Document:

Prepared by R.R. Donnelley Financial -- EX-4.2

 Exhibit 4.2 

Execution Copy 
 XDX,
INC. 
  
  

SIXTH AMENDED AND RESTATED INVESTORS’ RIGHTS AGREEMENT 

 
  

 Execution Copy 

TABLE OF CONTENTS 
  

									
	 	  	 	  	 	  	Page	 
			
	1.	  	Information and Other Rights.	  	 	1	  
				
		  	1.1	  	Annual Financial Statements	  	 	1	  
		  	1.2	  	Quarterly Financial Statements	  	 	2	  
		  	1.3	  	Annual Budget and Business Plan	  	 	2	  
		  	1.4	  	Additional Information	  	 	2	  
		  	1.5	  	Proprietary Information Agreements	  	 	2	  
		  	1.6	  	Market Stand-Off	  	 	3	  
		  	1.7	  	Independent Accountants	  	 	3	  
		  	1.8	  	Transfer of Information Rights	  	 	3	  
		  	1.9	  	Confidentiality, Right to Conduct Activities; Excluded Opportunities	  	 	3	  
		  	1.10	  	Termination of Covenants	  	 	4	  
		  	1.11	  	Board Observation Rights	  	 	4	  
			
	2.	  	Registration Rights	  	 	5	  
				
		  	2.1	  	Certain Definitions	  	 	5	  
		  	2.2	  	Demand Registration	  	 	6	  
		  	2.3	  	Piggyback Registration.	  	 	8	  
		  	2.4	  	Registration on Form S-3	  	 	9	  
		  	2.5	  	Expenses of Registration	  	 	10	  
		  	2.6	  	Registration Procedures	  	 	10	  
		  	2.7	  	Delay of Registration	  	 	12	  
		  	2.8	  	Indemnification	  	 	12	  
		  	2.9	  	Information by Holder	  	 	14	  
		  	2.10	  	Rule 144 Reporting	  	 	14	  
		  	2.11	  	Transfer of Registration Rights	  	 	15	  
		  	2.12	  	Standoff Agreement	  	 	15	  
		  	2.13	  	Limitation on Subsequent Registration Rights	  	 	15	  
		  	2.14	  	Termination of Registration Rights	  	 	16	  
			
	3.	  	Preemptive Rights	  	 	16	  
				
		  	3.1	  	General	  	 	16	  
		  	3.2	  	Right of First Refusal	  	 	16	  
		  	3.3	  	Offer After Sale to Third Parties	  	 	17	  
		  	3.4	  	Expiration of Right of First Refusal	  	 	17	  
			
	4.	  	Miscellaneous	  	 	18	  
				
		  	4.1	  	Waivers and Amendments	  	 	18	  
		  	4.2	  	Notices	  	 	18	  
		  	4.3	  	Descriptive Headings	  	 	18	  
		  	4.4	  	Governing Law	  	 	18	  
		  	4.5	  	Counterparts	  	 	18	  
		  	4.6	  	Expenses	  	 	19	  

  
 i 

 TABLE OF CONTENTS 

(continued) 
  

									
	 	  	 	  	 	  	Page	 
		  	4.7	  	Successors and Assigns	  	 	19	  
		  	4.8	  	Entire Agreement	  	 	19	  
		  	4.9	  	Separability; Severability	  	 	19	  
		  	4.10	  	Stock Splits	  	 	19	  
		  	4.11	  	Aggregation of Stock	  	 	19	  
		  	4.12	  	Additional Investors	  	 	19	  

  
 ii 

 XDX, INC. 

SIXTH AMENDED AND RESTATED INVESTORS’ RIGHTS AGREEMENT 

THIS SIXTH AMENDED AND RESTATED INVESTORS’ RIGHTS AGREEMENT (this “Agreement”) is made as of July 1, 2009, as amended on
March 29, 2012, by and among XDx, Inc., a Delaware corporation (the “Company”) and the undersigned holders of the Company’s Series A Preferred Stock (the “Series A Preferred”), Series B Preferred Stock (the “Series
B Preferred”), Series C Preferred Stock (the “Series C Preferred”), Series D Preferred Stock (the “Series D Preferred”), Series E Preferred Stock (the “Series E Preferred”), Series F Preferred Stock (the
“Series F Preferred”) and Series G Preferred Stock (the “Series G Preferred”) listed on Exhibit A hereto (each an “Investor”, and collectively, the “Investors”). 

Recitals 
 WHEREAS,
the Company, and holders of Series A Preferred, Series B Preferred, Series C Preferred, Series D Preferred, Series E Preferred and Series F Preferred have entered into that certain Fifth Amended and Restated Investors’ Rights Agreement, dated
as of May 7, 2007, as amended May 16, 2008 (the “Existing Agreement”); 
 WHEREAS, the Company and certain Investors
have entered into a Series G Preferred Stock Purchase Agreement dated as of July 1, 2009 or will enter into that certain 2012 Series G Preferred Stock Purchase Agreement dated on or about April 6, 2012 (each such purchase agreement, as
amended, a “Series G Agreement” and together, the “Series G Agreements”); 
 WHEREAS, certain Investors desire to obtain
certain rights (“Registration Rights”) regarding registration of the Company’s securities under the Securities Act (as defined below), certain preemptive rights regarding the Company’s equity offerings (“Preemptive
Rights”), and certain rights to information (“Information Rights”); and 
 WHEREAS, as a condition of the closing of the
financing provided for in the Series G Agreements, and as a material inducement to the financing of the Company provided for therein, the Company and the Investors desire to amend and restate in full the Existing Agreement, in the form set forth
herein. 
 NOW, THEREFORE, the parties agree as follows: 

1. Information and Other Rights.

1.1 Annual Financial Statements. So long as an Investor (and its affiliates) holds at least 700,000 shares (as adjusted for stock
splits, reverse stock splits, stock dividends, recapitalizations and similar events) of the Company’s Preferred Stock (including any shares of Common Stock issued or issuable upon conversion of Preferred Stock) (such an Investor, a “Major
Investor”), the Company will provide to such Major Investor as soon as practicable after the end of each fiscal year, and in any event within 90 days thereafter, a consolidated balance sheet of the Company and its subsidiaries, if any, as of
the end of such fiscal year, and consolidated statements of income, stockholders’ equity and cash flows of the Company and its 

  
 1 

 
subsidiaries, if any, for such year, prepared in accordance with generally accepted accounting principles in the United States (“GAAP”) and setting forth in each case in comparative
form the figures for the previous fiscal year, all in reasonable detail and all audited by a nationally recognized public accounting firm. 

1.2 Quarterly Financial Statements. The Company shall provide each Major Investor as soon as practicable after the end of each
quarter, and in any event within 30 days thereafter, a consolidated balance sheet of the Company and its subsidiaries, if any, as of the end of each such quarter, consolidated statements of income, and a consolidated statement of cash flow of the
Company and its subsidiaries for such period and for the current fiscal year to date, and setting forth in each case in comparative form the figures for corresponding periods in the previous fiscal year, and setting forth in comparative form the
budgeted figures for such period and for the current fiscal year then reported, prepared in accordance with GAAP consistently applied with prior practice for earlier periods (with the exception of footnotes that may be required by GAAP and provided
that the foregoing shall not restrict the right of the Company to change its accounting principles consistent with GAAP, if the Board of Directors of the Company (the “Board of Directors”) determines that it is in the best interest of the
Company to do so), subject to changes resulting from year-end audit adjustments, all in reasonable detail and signed by the principal financial or accounting officer of the Company. 

1.3 Annual Budget and Business Plan. The Company shall provide each Major Investor as soon as practicable, but in any event at
least thirty (30) days prior to the end of each fiscal year, a budget and business plan for the next fiscal year, prepared on a monthly basis, including balance sheets, projected profit or loss for the year and sources and applications of funds
statements for such months, and as soon as prepared, any other budgets or revised budgets prepared by the Company. 
 1.4 Additional
Information. The Company will allow each Major Investor to visit and inspect any of the properties of the Company (upon reasonable advance notice) and will deliver or provide to such Major Investor with reasonable promptness,
(i) copies of all notices, minutes, consents and the like provided to the Board of Directors, and (ii) such other information and data, including access to books, records, officers and accountants, with respect to the Company and its
subsidiaries as any such Major Investor may from time to time reasonably request; provided, however, that the Company shall not be obligated to provide any information that it considers in good faith to be a trade secret or to contain confidential
or classified information. The Company will maintain true books and records of account in which full and correct entries will be made of all its business transactions pursuant to a system of accounting established and administered in accordance with
GAAP consistently applied (except as noted therein) and will set aside on its books all such proper accruals and reserves as shall be required under GAAP consistently applied. 

1.5 Proprietary Information Agreements. The Company agrees to require each employee of the Company to execute a standard Proprietary
Information Agreement and each consultant and advisor of the Company to execute an agreement that provides for confidential treatment of the Company’s proprietary information and the assignment of inventions developed during such
individual’s relationship with the Company, as a condition of employment or consulting relationship or continued employment or consulting relationship, as the case may be, unless otherwise approved by the Board of Directors. 

  
 2 

 1.6 Market Stand-Off. The Company hereby covenants and agrees that, except as
otherwise approved by the Board of Directors, it shall be a condition of any issuance by the Company to any person or entity of shares of capital stock of the Company or any options, warrants or other rights to subscribe to or acquire any capital
stock of the Company, that such person or entity execute and deliver to the Company a market stand-off agreement in writing with, at a minimum, substantially similar terms as those set forth in Section 2.12 (but permitting an extension of the
lock-up period for up to 18 days) and covering all shares of capital stock owned by such person or entity or issuable upon exercise of any options, warrants or other rights to subscribe for or acquire the Company’s capital stock. 

1.7 Independent Accountants. The Company will retain independent pubic accountants of recognized national standing who shall certify the
Company’s financial statements at the end of each fiscal year. In the event the services of the independent public accountants so selected, or any firm of independent public accountants hereafter employed by the Company, are terminated, the
Company will promptly notify the Investors and will request the firm of independent public accountants whose services are terminated to deliver to the Investors a letter from such firm setting forth the reasons for the termination of their services.
In its notice to the Investors, the Company shall state whether the change of accountants was recommended or approved by the Board of Directors or any committee thereof. In the event of such termination, the Company will promptly thereafter engage
another firm of independent public accountants of recognized national standing. 
 1.8 Transfer of Information Rights. The rights
granted to the Investors under this Section 1 may be assigned to a transferee or assignee in connection with (i) any transfer or assignment of Preferred Stock by an Investor of not less than 50,000 shares (or any lesser amount if all of
such Investor’s Preferred Stock are transferred or assigned to a transferee) of Preferred Stock, (ii) any transfer or assignment of Preferred Stock by an Investor to any subsidiary, parent, member, affiliate, general partner, limited
partner, retired partner, retired member or shareholder of such Investor or the estate of such constituent partner or affiliate, or (iii) to any transferee or assignee who is a family member of the Investor or a trust for the benefit of the
Investor or any family member of the Investor, provided that, with respect to each such transfer or assignment, the Company be given prior written notice of the transfer and that such transfer otherwise be effected in accordance with applicable
securities laws. 
 1.9 Confidentiality, Right to Conduct Activities; Excluded Opportunities. Each Investor agrees, severally and not
jointly, to keep confidential and not use or disclose any information furnished to it by the Company which the Company identifies in writing as being proprietary or confidential (“Company Confidential Information”), except such use or
disclosure as is reasonably related to managing Investor’s investment in the Company and subject to confidentiality restrictions at least as restrictive as those set forth herein. Notwithstanding the foregoing, Integral Capital Partners may use
Company Confidential Information in the normal course of its investment business in connection with the purchase and sale of securities of public companies. Company Confidential Information shall not include information that (a) was in the
public domain prior to the time it was furnished by the Company, (b) is or becomes (through no 

  
 3 

 
willful improper action or inaction by such Investor) generally available to the public, (c) was in Investor’s possession or known by such Investor without restriction prior to receipt
from the Company, (d) was rightfully disclosed to such Investor by a third party without restriction or (e) was independently developed without any use of any Company Confidential Information. The Company acknowledges and agrees that
Bristol-Myers Squibb Company (“BMS”) is a biopharmaceutical company, and as such engages in research and development activities and collaborates and invests in numerous companies, some of which activities and investments may be competitive
with the Company’s business. BMS shall not be liable to the Company or any stockholder of the Company or any other Investor for any claim arising out of, or based upon, (i) the investment or collaboration by BMS in any entity
competitive to the Company, (ii) the conduct of any activities by BMS which may be competitive to Company, or (iii) actions taken by any employee, officer or other representative of BMS to assist any such competitive company, whether or
not such action was taken as a board member of such competitive company, or otherwise, and whether or not such action has a detrimental effect on the Company; provided, however, that BMS does not use or disclose any Company Confidential
Information in connection with such activities and any BMS representative who serves as a director of the Company shall disclose any direct or indirect interests in addition to and/or different from those of the Company wherever applicable
.. The Company hereby renounces any interest or expectancy of the Company in, or in being offered an opportunity to participate in, or receive any information related to any such competing activities or investments. 

1.10 Termination of Covenants. The rights set forth in this Section 1 shall terminate and be of no further force or effect
(i) upon the closing of the initial public offering of the Company’s securities pursuant to an effective registration statement filed under the Securities Act that results in the automatic conversion of all of the Company’s Preferred
Stock, or (ii) at such time as the Company becomes subject to the reporting requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), and is not exempt therefrom. 

1.11 Board Observation Rights.

(a) One representative chosen by BMS that is reasonably acceptable to the Board of Directors of the Company, shall have the right to attend
all sessions of all meetings of the Board of Directors of the Company (other than Closed Sessions), including the right to participate in any telephonic meetings of the Board, so long as BMS holds at least 50% of the shares of the Company stock
originally purchased by BMS (as adjusted for stock splits, dividends, recapitalizations, mandatory or optional conversions and the like). Said representative shall be provided with notice of meetings in the same manner at the same time as members of
the Board of Directors and shall be provided with any materials distributed to the Board of Directors in connection with such board meetings (other than Closed Session materials). Board materials that are sent to the directors, including copies of
all minutes, consents and other material (other than Closed Session minutes and materials) shall at the same time be sent by the Company via email to the designated representative of BMS. The foregoing visitation and information rights will not
apply to any Closed Sessions of any meeting or teleconference of the Board of Directors. For purposes of this Section 1.11, a “Closed Session” shall mean that part of any meeting or teleconference of the Board of Directors where a
majority of the Board determines that the exclusion of observers is necessary to protect the interests of the Company and its stockholders, 

  
 4 

 
to preserve the attorney-client privilege, or to protect commercially sensitive or confidential information. The rights set forth in this Section 1.11 shall terminate upon a Liquidation
Event (as defined in the Amended and Restated Certificate of Incorporation of the Company) or upon the closing of a firm commitment underwritten public offering pursuant to an effective registration statement on Form S-1 or any successor form under
the Securities Act, covering the offer and sale of Common Stock for the account of the Company to the public with gross proceeds to the Company in excess of $45,000,000 and a pre-money valuation (defined as the product of (A) of the number of
shares of Common Stock outstanding immediately prior to the closing of such offering, treating all outstanding shares of Preferred Stock as converted into Common Stock, multiplied by (B) the price to public in such offering) of at least
$225,000,000. 
 (b) BMS acknowledges that the confidential information received by it pursuant to the rights provided in this
Section 1.11 shall be deemed to be Company Confidential Information and subject to the terms of Section 1.9 hereof. 
 (c) This
Section 1.11 shall not be amended or waived without the written consent of BMS, provided that the foregoing shall not preclude the Company from granting separate observation rights to other parties without the consent of BMS. 

2. Registration Rights.
 2.1
Certain Definitions. As used in this Agreement, the following terms shall have the following respective meanings.
 (a)
“Commission” shall mean the Securities and Exchange Commission or any other federal agency at the time administering the Securities Act. 

(b) “Holder” shall mean the Investors holding Registrable Securities or securities convertible or exercisable into
Registrable Securities and any person holding such securities to whom the rights under this Section 2 have been transferred in accordance with Section 2.11 hereof. 

(c) “Initiating Holders” shall mean any Holder or Holders who in the aggregate hold at least 40% of the Registrable
Securities. 
 (d) “Participating Holders” shall mean any Holder or Holders who propose to distribute their securities
through a registration pursuant to this Section 2. 
 (e) “Preferred Stock” shall mean the Series A Preferred, the
Series B Preferred, the Series C Preferred, the Series D Preferred, the Series E Preferred, the Series F Preferred and the Series G Preferred. 

(f) “Registrable Securities” means (i) any shares of Common Stock issued or issuable upon conversion of Preferred Stock
issued by the Company (or Preferred Stock issued or issuable upon exercise of warrants issued by the Company) and (ii) any shares of Common Stock of the Company issued or issuable in respect of the Preferred Stock or other securities issuable
pursuant to the conversion of the Preferred Stock or upon any stock split, stock dividend, recapitalization, or similar event provided however that shares of Common Stock 

  
 5 

 
or other securities shall only be treated as Registrable Securities for purposes of Section 2.3 hereof if and so long as they have not been (A) sold to or through a broker or dealer or
underwriter in a public distribution or a public securities transaction, or (B) transferred in a transaction pursuant to which the registration rights are not also assigned in accordance with Section 2.11 hereof. 

(g) The terms “register,” “registered” and “registration” refer to a registration effected
by preparing and filing a registration statement in compliance with the Securities Act, and the declaration or ordering of the effectiveness of such registration statement. 

(h) “Registration Expenses” shall mean all expenses incurred by the Company in complying with Sections 2.2, 2.3 and 2.4
hereof, including the reasonable fees (not to exceed $50,000) of one special counsel to the selling stockholders (but excluding Selling Expenses). 

(i) “Restricted Securities” shall mean the securities of the Company required to bear a legend indicating that transfer is
restricted in the absence of registration. 
 (j) “Securities Act” shall mean the Securities Act of 1933, as amended, or any
similar federal statute and the rules and regulations of the Commission thereunder, all as the same shall be in effect at the time. 
 (k)
“Selling Expenses” shall mean all underwriting discounts, selling commissions and stock transfer taxes, if any, applicable to the securities registered by the Holders. 

2.2 Demand Registration.
 (a)
Request for Registration. In case the Company shall receive from Initiating Holders a written request that the Company effect any registration, qualification or compliance with respect to shares of Registrable Securities with an expected
aggregate offering price to the public of at least $25,000,000, the Company will (1) within ten days of the receipt by the Company of such notice, give written notice of the proposed registration, qualification or compliance to all other
Holders and (2) use its commercially reasonable best efforts to effect as soon as practicable (but in any event within 120 days after receipt of the request of the Initiating Holders) such registration, qualification or compliance (including,
without limitation, appropriate qualification under applicable blue sky or other state securities laws and appropriate compliance with applicable regulations issued under the Securities Act and any other governmental requirements or regulations) as
may be so requested and as would permit or facilitate the sale and distribution of all or such portion of such Registrable Securities as are specified in such request, together with all or such portion of the Registrable Securities of any Holder or
Holders joining in such request as are specified in a written request received by the Company within 20 days after receipt of such written notice from the Company; provided, however, that the Company shall not be obligated to take any action to
effect any such registration, qualification or compliance pursuant to this Section 2.2(a): 
 (i) In any particular jurisdiction in
which the Company would be required to execute a general consent to service of process in effecting such registration, qualification or compliance unless the Company is already subject to service in such jurisdiction and except as may be required by
the Securities Act; 

  
 6 

 (ii) Prior to the earlier of three (3) years following the date of this Agreement or six
months after the effective date of the Company’s first registered public offering of its securities; 
 (iii) During the period
starting with the date 60 days prior to the Company’s good faith estimate of the date of filing of, and ending on the date six months immediately following the effective date of, any registration statement pertaining to securities of the
Company (other than a registration of securities in a Rule 145 transaction, with respect to an employee benefit plan or with respect to the Company’s first registered public offering of its stock), provided that the Company is actively
employing in good faith all reasonable efforts to cause such registration statement to become effective and the Company delivers notice of such intent to the Initiating Holders within 15 days of the registration request; 

(iv) After the Company has effected two registrations pursuant to this Section 2.2(a), which registrations have been declared or ordered
effective and the securities offered pursuant to such registrations have been sold; or 
 (v) If the Company shall furnish to such Holders a
certificate signed by the President of the Company stating that in the good faith judgment of the Board of Directors it would be seriously detrimental to the Company or its stockholders for a registration statement to be filed in the near future,
then the Company’s obligation to use its best efforts to register, qualify or comply under this Section 2.2 shall be deferred for a period not to exceed 90 days from the date of receipt of written request from the Initiating Holders;
provided, however, that the Company shall not exercise such right more than once in any twelve-month period. 
 (b) Underwriting. In
the event that a registration pursuant to this Section 2.2 is for a registered public offering involving an underwriting, the Company shall so advise the Holders as part of the notice given pursuant to Section 2.2(a). In such event, the
right of any Holder to registration pursuant to this Section 2.2 shall be conditioned upon such Holder’s participation in the underwriting arrangements required by this Section 2.2, and the inclusion of such Holder’s Registrable
Securities in the underwriting to the extent requested shall be limited to the extent provided herein. 
 The Company shall, together with
all Participating Holders, enter into an underwriting agreement in customary form with the managing underwriter selected for such underwriting by the Company and reasonably acceptable to Initiating Holders holding a majority of Registrable
Securities held by all Initiating Holders. Notwithstanding any other provision of this Section 2.2, if the managing underwriter advises the Company in writing that marketing factors require a limitation of the number of shares to be
underwritten, then the Company shall so advise all Holders of Registrable Securities and the number of shares of Registrable Securities that may be included in the registration and underwriting shall be allocated among all Holders thereof in
proportion, as nearly as practicable, to the respective amounts of Registrable Securities held by such Holders at the time of filing the registration statement or in such other manner as shall be agreed to by the Company and Holders of a majority of
the Registrable Securities proposed to be 

  
 7 

 
included in such registration; provided, however, that the number of shares of Registrable Securities to be included in such underwriting shall not be reduced unless all other securities,
including securities for the Company’s account (i.e., primary shares), are first entirely excluded from the underwriting. No Registrable Securities excluded from the underwriting by reason of the underwriter’s marketing limitation shall be
included in such registration. To facilitate the allocation of shares in accordance with the above provisions, the Company or the underwriters may round the number of shares allocated to any Holder to the nearest 100 shares. 

If any Holder of Registrable Securities disapproves of the terms of the underwriting, such Holder may elect to withdraw therefrom by written
notice to the Company, the managing underwriter and the Initiating Holders. The Registrable Securities and/or other securities so withdrawn shall also be withdrawn from registration, and such Registrable Securities shall not be transferred in a
public distribution prior to 90 days after the effective date of such registration, or such other shorter period of time as the underwriters may require. If shares are withdrawn from registration, the Company shall offer to all persons retaining the
right to include securities in the registration the right to include additional securities in the registration, with such shares being allocated among all such Participating Holders in proportion, as nearly as practicable, to the respective amounts
of Registrable Securities held by such Participating Holders at the time of filing the registration statement. 
 2.3 Piggyback
Registration.
 (a) Notice of Registration. If at any time or from time to time the Company shall determine to register any of its
securities, either for its own account or the account of a security holder or holders, other than a registration relating solely to employee benefit plans, a registration relating solely to a Commission Rule 145 transaction, or a registration
pursuant to Section 2.2 hereof, the Company will (i) promptly give to each Holder written notice thereof, and (ii) include in such registration (and any related qualification under blue sky laws or other compliance), and in any
underwriting involved therein, all the Registrable Securities specified in a written request or requests, made within 15 days after receipt of such written notice from the Company, by any Holder. Such written requests may include all or a portion of
the Holder’s Registrable Securities. 
 (b) Underwriting. If the registration of which the Company gives notice is for a
registered public offering involving an underwriting, the Company shall so advise the Holders as a part of the written notice given pursuant to 2.3(a). In such event the right of any Holder to registration pursuant to 2.3 shall be conditioned upon
such Holder’s participation in such underwriting and the inclusion of Registrable Securities in the underwriting to the extent provided herein. All Holders proposing to distribute their securities through such underwriting shall (together with
the Company) enter into an underwriting agreement in customary form with the managing underwriter selected for such underwriting by the Company. Notwithstanding any other provision of this Section 2.3, if the managing underwriter determines
that marketing factors require a limitation of the number of shares to be underwritten, the managing underwriter may limit the Registrable Securities and other securities to be distributed through such underwriting; provided, however, that, in no
event shall any Registrable Securities be so limited unless all other securities of the Company (other than shares for the Company’s account (i.e., primary shares)) are excluded in full from such offering; provided, further, that in no event
shall the number of 

  
 8 

 
Registrable Securities included in such registration be reduced to less than 20% of the total number of securities to be included in such registration except in connection with the Company’s
initial public offering, in which case all Registrable Securities may be excluded in full. The Company shall so advise all Holders distributing their securities through such underwriting of such limitation (or exclusion, if applicable) and the
number of shares of Registrable Securities that may be included in the registration and underwriting shall be allocated (if applicable) among all such Holders in proportion, as nearly as practicable, to the respective amounts of Registrable
Securities held by such Holders at the time of filing the registration statement. To facilitate the allocation of shares in accordance with the above provisions, the Company may round the number of shares allocated to any Holder or holder to the
nearest 100 shares. 
 If any Holder of Registrable Securities disapproves of the terms of any such underwriting, such Holder may elect to
withdraw therefrom by written notice to the Company and the managing underwriter. Any securities excluded or withdrawn from such underwriting shall be withdrawn from such registration, and shall not be transferred in a public distribution prior to
90 days after the effective date of the registration statement relating thereto, or such other shorter period of time as the underwriters may require. If shares are withdrawn from registration, the Company shall offer to all persons retaining the
right to include securities in the registration the right to include additional securities in the registration, with such shares being allocated among all such Participating Holders in proportion, as nearly as practicable, to the respective amounts
of Registrable Securities held by such Participating Holders at the time of filing the registration statement. 
 (c) Right to Terminate
Registration. The Company shall have the right to terminate or withdraw any registration initiated by it under this Section 2.3 prior to the effectiveness of such registration whether or not any Holder has elected to include securities in
such registration. The Registration Expenses of such withdrawn registration shall be borne by the Company in accordance with Section 2.5 hereof. 

2.4 Registration on Form S-3.

(a) Request for Registration. Following the Company’s initial public offering, the Company shall use its best efforts to become
eligible to register offerings of securities on Commission Form S-3 or its successor form. After the Company has qualified for the use of Form S-3, Holders of Registrable Securities shall have the right to request registration on Form S-3 (which
request shall be in writing and shall state the number of shares of Registrable Securities to be registered and the intended method of disposition of shares by such Holders), and upon receiving such request the Company shall (1) within ten days
of the receipt by the Company of such request, give written notice of the proposed registration to all other Holders and (2) use its best efforts to effect such registration as soon as practicable, and in any event within 120 days of such
request, together with all or such portion of the Registrable Securities of any Holder or Holders joining in such request as specified in a written request received by the Company within 20 days after receipt by the other Holders of the written
notice from the Company referenced above in (1). The Company shall not be obligated to take any action to effect any such registration, qualification or compliance pursuant to this Section 2.4(a): 

  
 9 

 (i) unless the Holders requesting registration propose to dispose of Registrable Securities
having an anticipated aggregate price to the public (before deduction of underwriting discounts and expenses of sale) of at least $1,000,000; 

(ii) during the period starting with the date 60 days prior to the Company’s estimated date of filing of, and ending on the date three
months immediately following the effective date of, any registration statement pertaining to securities of the Company (other than a registration of securities in a Rule 145 transaction or with respect to an employee benefit plan), provided that the
Company is actively employing in good faith all reasonable efforts to cause such registration statement to become effective and the Company delivers notice of such intent to the applicable Holders within 15 days of the registration request; 

(iii) more than twice in any twelve-month period; or 

(iv) if the Company shall furnish to such Holders a certificate signed by the President of the Company stating that in the good faith judgment
of the Board of Directors it would be seriously detrimental to the Company or its stockholders for registration statements to be filed in the near future, then the Company’s obligation to use its best efforts to file a registration statement
under this Section 2.4 shall be deferred for a period not to exceed 90 days from the receipt of the request to file such registration by such Holder or Holders; provided, however, that the Company shall not exercise such right more than once in
any twelve-month period. 
 (b) Underwriting Procedures. If a registration required under this Section 2.4 is for an
underwritten offering, the provisions of Sections 2.2(b) shall apply. 
 2.5 Expenses of Registration. All Registration Expenses
incurred in connection with registrations pursuant to Sections 2.2, 2.3 and 2.4 shall be borne by the Company. All Selling Expenses relating to securities registered on behalf of any Holder shall be borne by such Holder. 

2.6 Registration Procedures. In the case of each registration, qualification or compliance effected by the Company pursuant to this
Section 2, the Company will keep each Holder advised in writing as to the initiation of each registration, qualification and compliance and as to the completion thereof. At its expense the Company will use its commercially reasonable best
efforts to: 
 (a) Prepare and file with the Commission a registration statement with respect to such securities and use its best efforts to
cause such registration statement to become and remain effective for at least ninety (90) days or until the distribution described in the Registration Statement has been completed (up to a maximum of 120 days); provided, however,
that in the case of any registration of Registrable Securities on Form S-3 which are intended to be offered on a continuous or delayed basis, such period shall be extended, if necessary, to keep the registration statement effective until all such
Registrable Securities are sold, provided that if Rule 415, or any successor rule under the Securities Act, permits an offering on a continuous or delayed basis, and provided further that if applicable rules under the Securities Act governing the
obligation to file a post-effective amendment permit, in lieu of filing a post-effective amendment 

  
 10 

 
which (i) includes any prospectus required by Section 10(a)(3) of the Securities Act or (ii) reflects facts or events representing a material or fundamental change in the
information set forth in the registration statement, the incorporation by reference of information required to be included in (i) and (ii) above shall be contained in periodic reports filed pursuant to Section 13 or 15(d) of the
Exchange Act in the registration statement. 
 (b) Prepare and file with the Commission such amendments and supplements to such registration
statement and the prospectus used in connection with such registration statement as may be necessary to comply with the provisions of the Securities Act with respect to the disposition of all securities covered by such registration statement. 

(c) Furnish to the Participating Holders and to the underwriters of the securities being registered such reasonable number of copies of the
registration statement, preliminary prospectus, final prospectus and such other documents as they may reasonably request in order to facilitate the public offering of such securities. 

(d) Use its commercially reasonable best efforts to register and qualify the securities covered by such registration statement under such
other securities or blue sky laws of such jurisdictions as shall be reasonably requested by the Participating Holders, provided that the Company shall not be required in connection therewith or as a condition thereto to qualify to do business or to
file a general consent to service of process in any such states or jurisdictions, unless the Company is already subject to service in such jurisdiction and except as may be required by the Securities Act. 

(e) In the event of any underwritten public offering, enter into and perform its obligations under an underwriting agreement, in usual and
customary form, with the managing underwriter of such offering. Each participating Holder shall also enter into and perform its obligations under such an agreement. 

(f) Notify each Participating Holder at any time when a prospectus relating thereto is required to be delivered under the Securities Act or
upon the happening of any event as a result of which the prospectus included in such registration statement, as then in effect, includes an untrue statement of a material fact or omits to state a material fact required to be stated therein or
necessary to make the statements therein, in light of the circumstances in which they were made, not misleading, in the light of the circumstances then existing, and, at the request of any Participating Holder, prepare and furnish to such
Participating Holder a reasonable number of copies of a supplement to or an amendment of such prospectus as may be reasonably necessary so that, as thereafter delivered to the purchaser of such shares, such prospectus shall not include an untrue
statement of a material fact or omit to state a material fact required to be stated therein or necessary to make the statements therein not misleading or incomplete in light of the circumstances then existing. 

(g) Cause all securities covered by such registration statement to be listed on each securities exchange or authorized for quotation on each
automated quotation system on which similar securities issued by the Company are then listed or authorized for quotation. 

  
 11 

 (h) Provide a transfer agent and registrar for all Registrable Securities covered by such
registration statement and a CUSIP number for all such Registrable Securities, in each case not later than the effective date of such registration. 

(i) Furnish, at the request of any Participating Holder, on the date that the securities are delivered to the underwriters for sale in
connection with a registration being sold through underwriters, (i) an opinion, dated such date, of the counsel representing the Company for the purposes of such registration, in form and substance as is customarily given to underwriters in an
underwritten public offering, addressed to the underwriters, if any, and to the Participating Holders and (ii) a letter dated such date, from the independent certified public accountants of the Company, in form and substance as is customarily
given by independent certified public accountants to underwriters in an underwritten public offering, addressed to the underwriters, if any, and to the Holders requesting registration of Registrable Securities. 

2.7 Delay of Registration. No Holder shall have any right to obtain or seek an injunction restraining or otherwise delaying any
such registration as the result of any controversy that might arise with respect to the interpretation or implementation of this Section 2. 

2.8 Indemnification. In the event any Registrable Securities are included in a registration statement under this Section 2:

 (a) To the extent permitted by law, the Company will indemnify each Participating Holder, each of its officers, directors, employees,
partners, members, affiliates, agents and legal counsel, and each person controlling such Participating Holder within the meaning of Section 15 of the Securities Act, with respect to which registration, qualification or compliance has been
effected pursuant to this Section 2, and each underwriter, if any, and each person who controls any underwriter within the meaning of Section 15 of the Securities Act, against all expenses, claims, losses, damages or liabilities (or
actions in respect thereof), including any of the foregoing incurred in settlement of any litigation, commenced or threatened, arising out of or based on any untrue statement (or alleged untrue statement) of a material fact contained in any
registration statement, prospectus, offering circular or other document, or any amendment or supplement thereto, incident to any such registration, qualification or compliance, or based on any omission (or alleged omission) to state therein a
material fact required to be stated therein or necessary to make the statements therein not misleading, or any violation by the Company of the Securities Act or any rule or regulation promulgated under the Securities Act applicable to the Company in
connection with any such registration, qualification or compliance, and the Company will pay to each such Participating Holder, each of its officers, directors, employees, partners, members, affiliates, agents and legal counsel and each person
controlling such Participating Holder, each such underwriter and each person who controls any such underwriter, as incurred, any legal and any other expenses reasonably incurred in connection with investigating, preparing, defending or settling any
such claim, loss, damage, liability or action, provided that the Company will not be liable to a particular Participating Holder in any such case to the extent that any such claim, loss, damage, liability or expense arises out of or is based on any
untrue statement or omission or alleged untrue statement or omission, made in reliance upon and in conformity with written information furnished to the Company by an instrument duly executed by such Participating Holder and stated to be specifically
for use therein. 

  
 12 

 (b) To the extent permitted by law, each Participating Holder, severally and not jointly, will,
if Registrable Securities held by such Participating Holder are included in the securities as to which such registration, qualification or compliance is being effected, indemnify the Company, each of its directors, officers, and legal counsel, each
underwriter, if any, of the Company’s securities covered by such a registration statement, each person who controls the Company or such underwriter within the meaning of Section 15 of the Securities Act, and each other Participating
Holder, each of its officers, directors, partners and legal counsel and each person controlling such Participating Holder within the meaning of Section 15 of the Securities Act, against all claims, losses, damages and liabilities (or actions in
respect thereof) arising out of or based on any untrue statement (or alleged untrue statement) of a material fact contained in any such registration statement, prospectus, offering circular or other document, or any omission (or alleged omission) to
state therein a material fact required to be stated therein or necessary to make the statements therein not misleading, and will pay the Company, such Participating Holders, such directors, officers, partners, underwriters or control persons, as
incurred any legal or any other expenses reasonably incurred in connection with investigating or defending any such claim, loss, damage, liability or action, in each case to the extent, but only to the extent, that such untrue statement (or alleged
untrue statement) or omission (or alleged omission) is made in such registration statement, prospectus, offering circular or other document in reliance upon and in conformity with written information furnished to the Company in an instrument duly
executed by such Participating Holder and stated to be specifically for use therein. Notwithstanding the foregoing, the liability of each Holder under this subsection (b) shall be limited to an amount equal to the net proceeds to each such
Holder of Registrable Securities sold as contemplated herein with respect to the applicable registration, unless such liability resulted from intentional misrepresentation by such Holder. A Holder will not be required to enter into any agreement or
undertaking in connection with any registration under this Section 2 providing for any indemnification or contribution on the part of such Holder greater than the Holder’s obligations under this Section 2.8(b). 

(c) Each party entitled to indemnification under this Section 2.8 (the “Indemnified Party”) shall give notice to the party
required to provide indemnification (the “Indemnifying Party”) promptly after such Indemnified Party has actual knowledge of any claim as to which indemnity may be sought, and shall permit the Indemnifying Party to assume the defense of
any such claim or any litigation resulting therefrom, provided that counsel for the Indemnifying Party, who shall conduct the defense of such claim or litigation, shall be approved by the Indemnified Party (whose approval shall not unreasonably be
withheld), and the Indemnified Party may participate in such defense at such party’s expense, and provided further that the failure of any Indemnified Party to give notice as provided herein shall not relieve the Indemnifying Party of its
obligations under this Section 2 except to the extent that the failure to give such notice is materially prejudicial to an Indemnifying Party’s ability to defend such action and provided further, that the Indemnifying Party shall not
assume the defense for matters as to which there is a conflict of interest or separate and different defenses but shall bear the expense of such defense nevertheless. No Indemnifying Party, in the defense of any such claim or litigation, shall,
except with the consent of each Indemnified Party, consent to entry of any judgment or enter into any settlement which does not include as an unconditional term thereof the giving by the claimant or plaintiff to such Indemnified Party of a full
release from all liability in respect to such claim or litigation. 

  
 13 

 (d) If the indemnification provided for in this Section 2.8 is held by a court of competent
jurisdiction to be unavailable to an Indemnified Party with respect to any claim, loss, damage, liability or action referred to therein, then the Indemnifying Party, in lieu of indemnifying such Indemnified Party hereunder, shall contribute to the
amount paid or payable by such Indemnified Party as a result of such claim, loss, damage, liability or action in such proportion as is appropriate to reflect the relative fault of the Indemnifying Party on the one hand and the Indemnified Party on
the other in connection with the actions that resulted in such claims, loss, damage, liability or action, as well as any other relevant equitable considerations. The relative fault of the Indemnifying Party and of the Indemnified Party shall be
determined by reference to, among other things, whether the untrue or alleged untrue statement of a material fact or the omission or alleged omission to state a material fact related to information supplied by the Indemnifying Party or by the
Indemnified Party and the parties’ relative intent, knowledge, access to information and opportunity to correct or prevent such statement or omission. The Company and the Holders agree that it would not be just and equitable if contribution
pursuant to this Section 2.8(d) were based solely upon the number of entities from whom contribution was requested or by any other method of allocation which does not take account of the equitable considerations referred to above in this
Section 2.8(d). Notwithstanding the foregoing, the liability of each Participating Holder under this subsection (d) shall be limited to an amount equal to the net proceeds to each such Participating Holder of Registrable Securities sold as
contemplated herein with respect to the applicable registration, unless such liability resulted from intentional misrepresentation by such Holder. 

(e) The indemnification obligations of the Company and the Holders under this Section 2.8 shall survive the completion of any offering of
Registrable Securities in a registration statement filed pursuant to this Agreement. 
 2.9 Information by Holder. It shall be a
condition precedent to the obligations of the Company to take any action pursuant to this Section 2 with respect to the Registrable Securities of any selling Holder that such holder shall furnish to the Company such information regarding
itself, the Registrable Securities held by it, and the intended method of disposition of such securities as shall be required to effect the registration of such Holder’s Registrable Securities. 

2.10 Rule 144 Reporting. With a view to making available the benefits of certain rules and regulations of the Commission which may
at any time permit the sale of the Restricted Securities to the public without registration, after such time as a public market exists for the Common Stock of the Company, the Company agrees to: 

(a) Make and keep public information available, as those terms are defined in Rule 144 under the Securities Act, at all times after the date
that the Company becomes subject to the reporting requirements of the Securities Act or the Exchange Act; 
 (b) File with the Commission in
a timely manner all reports and other documents required of the Company under the Securities Act and the Exchange Act (at any time after it has become subject to such reporting requirements); and 

  
 14 

 (c) So long as an Investor owns any Restricted Securities, furnish upon request, (i) a
written statement by the Company as to its compliance with the reporting requirements of said Rule 144, and of the Securities Act and the Exchange Act (at any time after it has become subject to such reporting requirements), (ii) a copy of the
most recent annual or quarterly report of the Company and (iii) such other reports and documents of the Company and other information in the possession of or reasonably obtainable by the Company as an Investor may reasonably request in availing
itself of any rule or regulation of the Commission allowing an Investor to sell any such securities without registration. 
 2.11 Transfer
of Registration Rights. The rights granted Holders under this Section 2 may be assigned (i) to a transferee or assignee in connection with any transfer or assignment of Registrable Securities by a Holder of not less than 50,000
shares (or any lesser amount if all of such Holder’s Registrable Securities are transferred or assigned to a transferee) of Registrable Securities, or (ii) to any subsidiary, parent, member, affiliate, general partner, limited partner,
retired partner, retired member or shareholder of a Holder or the estate of such constituent partner or affiliate, or to any transferee or assignee who is a family member of the Holder or a trust for the benefit of the Holder or any family member of
the Holder, provided that, with respect to each such transfer or assignment, the Company be given prior written notice of the transfer, the transferee or assignee agrees in writing to all provisions contained in this Section 2 and that such
transfer otherwise be effected in accordance with applicable securities laws. 
 2.12 Standoff Agreement. The Holder agrees in
connection with the Company’s initial public offering of the Company’s securities, upon request of the Company or the underwriters managing any underwritten offering of the Company’s securities, not to sell, make any short sale of,
loan, grant any option for the purchase of, or otherwise dispose of any the Company’s securities (other than those included in the registration) without the prior written consent of the Company or such underwriters, as the case may be, during
the 180 days beginning on the effective date of such registration statement, provided that each officer, director and 1% stockholder of the Company shall also have entered into a 180-day market stand-off agreement. The obligations described in this
Section 2.12 shall not apply to securities purchased in a public market transaction following the effective date of such registration statement or to a registration relating solely to employee benefit plans on Form S-1 or Form S-8 or similar forms that may be promulgated in the future, or a registration relating solely to a Commission Rule 145 transaction on Form S-4 or similar forms that may be promulgated in the future. Notwithstanding the foregoing, if the Company or the managing underwriter releases from the terms of the foregoing lockup or from any other lockup
provision any share of Common Stock or Preferred Stock held by any person or entity, the Company shall, within at least 5 days prior to such release, immediately so notify all other Holders, and all other Holders shall automatically upon such
release be released from their respective lockup provided for in this Section 2.12 and be allowed to transfer a proportionate amount of such Holder’s Registrable Securities subject thereto. 

2.13 Limitation on Subsequent Registration Rights. After the date of this Agreement, the Company shall not, without the prior
written consent of the Holders of 66 2/3% of the Registrable Securities then outstanding, enter into any agreement with any holder or prospective holder of any securities of the Company that would grant such holder registration rights senior or on
par with those granted to the Holders hereunder. 

  
 15 

 2.14 Termination of Registration Rights. The rights granted under this Section 2
shall terminate on the first to occur of (i) all shares of Registrable Securities held or entitled to be held upon conversion by such Holder may immediately be sold under Rule 144 under the Securities Act during any ninety (90) day
period; provided, however, that the provisions of this Section 2.14 shall not apply to any Holder who owns more than two percent (2%) of the Company’s outstanding stock until such time as such Holder owns less than two percent
(2%) of the outstanding stock of the Company and (ii) the five (5) year anniversary of the consummation of the initial underwritten public offering of the Company’s securities pursuant to an effective registration statement filed
under the Securities Act that results in the conversion of all of the Company’s Preferred Stock. 
 3. Preemptive Rights.

3.1 General. Except for (i) shares of Common Stock issued upon conversion of the Preferred Stock, (ii) securities issued
pursuant to a public offering pursuant to an effective registration statement under the Securities Act that results in the conversion of all of the then-outstanding Preferred Stock, (iii) securities issued pursuant to the acquisition of another
corporation by the Company by merger, purchase of substantially all of the assets, or other reorganization, in each case as approved by the Board of Directors, (iv) securities issued in connection with any stock split or stock dividend of the
Company, (v) shares of Common Stock issued to employees, officers, or directors of, or contractors, consultants or advisors to, the Company pursuant to stock purchase or stock option plans, stock bonuses or awards, contracts or other
arrangements that are approved by the Board of Directors, (vi) securities issued to financial institutions or lessors in connection with commercial credit arrangements, equipment financings or similar transactions, the primary purpose of which
is other than equity financing, as approved by the Board of Directors, (vii) shares of Series G Preferred issued pursuant to the Series G Agreements, and (viii) securities issued pursuant to options, warrants, notes or other rights to
acquire securities of the Company outstanding as of the date of this Agreement, the Company will not, nor will it permit any subsidiary to, authorize or issue any shares of stock of the Company of any class and will not authorize, issue or grant any
options, warrants, conversion rights or other rights to purchase or acquire any shares of stock of the Company of any class without offering the Major Investors the right of first refusal described below. 

3.2 Right of First Refusal. Each Major Investor shall have a right of first refusal to purchase an amount of securities of the
Company of any class or kind which the Company proposes to sell (other than the issuance of shares contemplated by subsections (i) through (vii) of Section 3.1 above) (“Preemptive Securities”) sufficient to maintain such
Major Investor’s Pro Rata Portion (as defined below). If the Company wishes to make any such sale of Preemptive Securities (a “Proposed Sale”), it shall give the Major Investors written notice of the Proposed Sale. The notice shall
set forth (i) the Company’s bona fide intention to offer Preemptive Securities and (ii) the material terms and conditions of the Proposed Sale (including the number of shares to be offered and the price, if any, for which the Company
proposes to offer such shares), and shall constitute an offer to sell Preemptive Securities to the Investors on such terms and conditions. Any Major Investor may accept such offer by delivering a written notice of acceptance (an “Acceptance
Notice”) to the Company within fifteen (15) days after receipt of the Company’s notice of the Proposed Sale. Any Major Investor exercising its right of first refusal shall be entitled to participate in the purchase of Preemptive
Securities on a pro rata basis to the 

  
 16 

 
extent necessary to maintain such Major Investor’s proportionate beneficial ownership interest in the Company (such Major Investor’s “Pro Rata Portion”). For purposes hereof,
a Major Investor’s Pro Rata Portion shall be determined by multiplying the number of Preemptive Securities by a fraction, (X) the numerator of which shall be the number of shares of Common Stock issued or issuable upon conversion of the
Preferred Stock held by such Major Investor and any other Common Stock held by such Major Investor (treating as fully converted into Common Stock any convertible, exercisable or exchangeable securities and other rights to acquire Common Stock held
by such Major Investor) and (Y) the denominator of which shall be the number of shares of Common Stock outstanding, into which any outstanding convertible securities may be converted and for which any outstanding options and outstanding
warrants may be exercised. The Company shall, in writing, inform each Investor which elects to purchase its full Pro Rata Portion of Preemptive Securities of any other Major Investor’s failure to purchase its full Pro Rata Portion, in which
case the Investors electing to purchase their full Pro Rata Portions shall have the right to purchase any shares any other Major Investors elect not to purchase on a pro rata basis. The closing of the sale of Preemptive Securities shall occur on the
later of the closing of the Proposed Sale or within ten days after the Major Investors are given written notice of the right to purchase any shares any other Major Investor elects not to purchase. If any Major Investor who elects to exercise its
right of first refusal does not complete the purchase of such Preemptive Securities within such period, then unless such failure is caused by or results from any action or inaction of the Company, the Company may complete the sale of Preemptive
Securities on the terms and conditions specified in the Company’s notice within the 60-day period following the expiration of such 10-day period. If the Company does not enter into an agreement for the sale of such shares within such 10-day
period, or if such agreement is not consummated within such 60-day period, the right provided hereunder shall be deemed to be revived and all future shares of Preemptive Securities shall not be offered unless first reoffered to the Major Investors
in accordance with this Section 3. A Major Investor shall be entitled to apportion the right of first refusal hereby granted among itself and its subsidiaries, parent, members, affiliates, partners and retired partners and members in such
proportions it deems appropriate. 
 3.3 Offer After Sale to Third Parties. In lieu of delivering to the Major Investors written
notice of a Proposed Sale prior to such Proposed Sale pursuant to Section 3.2, the Company may elect first to sell Preemptive Securities to third parties and then to offer to Major Investors (by written notice delivered to the Major Investors
within 5 days of the closing of the Proposed Sale) the opportunity to purchase their Pro Rata Portions of the Preemptive Securities (calculated giving effect to all sales of the Preemptive Securities, including sales to Major Investors). Such offer
shall remain in effect for 15 days (the “Acceptance Period”) after delivery of written notice to the Investors, and if accepted, the closing of the sale of Preemptive Securities to the Major Investors shall occur within ten days after the
expiration of the Acceptance Period. 
 3.4 Expiration of Right of First Refusal. The right of first refusal granted under this
Agreement shall expire upon the closing of a firm commitment underwritten public offering pursuant to an effective registration statement on Form S-1 or any successor form under the Securities Act, covering the offer and sale of Common Stock for the
account of the Company to the public with gross proceeds to the Company in excess of $45,000,000 and a pre-money valuation (defined as the product of (A) of the number of shares of Common Stock outstanding immediately prior to the closing of
such offering, treating all outstanding shares of Preferred Stock as converted into Common Stock, multiplied by (B) the price to public in such offering) of at least $225,000,000. 

  
 17 

 4. Miscellaneous.

4.1 Waivers and Amendments. With the written consent of the Company and the record or beneficial holders of a majority of the
Registrable Securities, the rights and obligations of the Company and the holders of Registrable Securities under this Agreement may be waived (either generally or in a particular instance, either retroactively or prospectively, and either for a
specified period of time or indefinitely) or amended; provided, however, that (i) no such amendment shall impose or increase any liability or obligation on an Investor or eliminate or decrease the rights of an Investor without the consent of
such Investor, and (ii) no such amendment shall have a disproportionately adverse effect on any Investor in relation to the other Investors without the consent of such Investor, and provided further, that no such modification, amendment or
waiver shall reduce the aforesaid percentage of Registrable Securities without the consent of all of the Purchasers of the Registrable Securities. Upon the effectuation of each such waiver, consent, agreement of amendment or modification, the
Company shall promptly give written notice thereof to the record holders of the Registrable Securities who have not previously consented thereto in writing. This Agreement or any provision hereof may be changed, waived, discharged or terminated only
by a statement in writing signed by the party against which enforcement of the change, waiver, discharge or termination is sought, except to the extent provided in this Section 4.1. 

4.2 Notices. Any notice required or permitted hereunder shall be given in writing and shall be conclusively deemed effectively
given (i) five days after sending by first class U.S. mail postage prepaid, (ii) upon personal delivery, or (iii) two days after the date of sending if sent by commercial overnight courier addressed to the Company at the
Company’s then current principal place of business (with a copy to Wilson Sonsini Goodrich & Rosati, 650 Page Mill Road, Palo Alto, California 94304, Attn: Michael J. Danaher), to an Investor, at such Holder’s or Investor’s
address as set forth on the records of the Company (with a copy to O’Melveny & Myers LLP, 2765 Sand Hill Road, Menlo Park, CA 94025, Attn: Sam Zucker), or at such other address as the Company or such Investor or Holder may designate.

 4.3 Descriptive Headings. The descriptive headings herein have been inserted for convenience only and shall not be deemed to
limit or otherwise affect the construction of any provisions hereof. 
 4.4 Governing Law. This Agreement and all acts and
transactions pursuant hereto and the rights and obligations of the parties hereto shall be governed, construed and interpreted in accordance with the laws of the State of California, without giving effect to principles of conflicts of law. 

4.5 Counterparts. This Agreement may be executed in one or more counterparts, including those transmitted via facsimile or
electronic mail, each of which shall for all purposes be deemed to be an original and all of which shall constitute the same instrument, but only one of which need be produced. 

  
 18 

 4.6 Expenses. If any action at law or in equity is necessary to enforce or interpret
the terms of this Agreement, the prevailing party shall be entitled to reasonable attorney’s fees, costs and necessary disbursements in addition to any other relief to which such party may be entitled. 

4.7 Successors and Assigns. Except as otherwise expressly provided in this Agreement, this Agreement shall benefit and bind the
successors, assigns, heirs, executors and administrators of the parties to this Agreement; provided, however, that (i) no rights or obligations under this Agreement may be assigned by the Company and (ii) no rights or obligations of any
Investor under this Agreement may be assigned apart from the related shares of capital stock which are subject to this Agreement. 
 4.8
Entire Agreement. This Agreement constitutes the full and entire understanding and agreement between the parties with regard to the subject matter of this Agreement. 

4.9 Separability; Severability. Unless expressly provided in this Agreement, the rights of each Investor under this Agreement are
several rights, not rights jointly held with any other Investors. Any invalidity, illegality or limitation on the enforceability of this Agreement with respect to any Investor shall not affect the validity, legality or enforceability of this
Agreement with respect to the other Investors. If any provision of this Agreement is judicially determined to be invalid, illegal or unenforceable, the validity, legality and enforceability of the remaining provisions shall not be affected or
impaired. 
 4.10 Stock Splits. All references to numbers of shares in this Agreement shall be appropriately adjusted to reflect
any stock dividend, split, combination or other recapitalization of shares by the Company occurring after the date of this Agreement. 
 4.11
Aggregation of Stock. All shares of Preferred Stock held or acquired by affiliated entities or persons shall be aggregated together for the purpose of determining the availability of any rights under this Agreement. 

4.12 Additional Investors. Any party who purchases Preferred Stock from the Company on or after the date of this Agreement,
including any additional purchase under the Series G Agreements, may be added as an “Investor” under this Agreement without the consent of Investors already party to this Agreement and without the need to amend this Agreement.
Notwithstanding anything to the contrary in this Agreement, to become a party to this Agreement, such new Investor shall execute and deliver a counterpart signature page to this Agreement and Exhibit A to this Agreement shall then be supplemented
with applicable information concerning such Investor. 
 [This space intentionally left blank] 

  
 19 

 IN WITNESS WHEREOF, the parties have executed this Sixth Amended and Restated Investors’
Rights Agreement on the date first set forth above. 
  

							
	THE COMPANY:	 		 	XDX, INC.
		 		 	a Delaware corporation
				
		 		 	By:	 	 /s/ Pierre Cassigneul

		 		 		 	Pierre Cassigneul, President
			
		 		 	Address:
		 		 	3260 Bayshore Blvd.
		 		 	Brisbane, CA 94005

 [Signature Page to XDx, Inc. Sixth Amended and Restated Investors’ Rights Agreement] 

							
	THE INVESTORS:	 		 	INTEL CAPITAL (Cayman) CORPORATION,
		 		 	a Cayman Islands corporation
				
		 		 	By:	 	 /s/ Jose M. Blanc

		 		 	Name:	 	Jose M. Blanc
		 		 	Title:	 	Managing Director
			
		 		 	 Intel Capital Corporation,
 a
Delaware corporation

				
		 		 	By:	 	 /s/ Jose M. Blanc

		 		 	Name:	 	Jose M. Blanc
		 		 	Title:	 	Managing Director
			
		 		 	 Intel Capital Corporation
 c/o Intel
Corporation

		 		 	Attn: Intel Capital Portfolio Manager
		 		 	2200 Mission College Blvd., M/S RN6-46
		 		 	Santa Clara, CA 95052
		 		 	Fax Number: (408) 765-6038
		 		 	With a copy by e-mail to:
		 		 	portfolio.manager@intel.com
			
		 		 	 THIS IS THE SIGNATURE PAGE FOR THE XDX, INC.

(THE “COMPANY”) SIXTH AMENDED AND
 RESTATED
INVESTORS’ RIGHTS AGREEMENT
 ENTERED INTO BY AND BETWEEN THE COMPANY,

INTEL CAPITAL CORPORATION AND THE OTHER
 INVESTORS SET
FORTH THEREIN.

 [Signature Page to XDx, Inc. Sixth Amended and Restated Investors’ Rights Agreement] 

									
	THE INVESTORS:	 		 	DAG VENTURES QP, L.P.
				
		 		 	By:	 	 DAG Ventures Management, LLC,
 its
General Partner

					
		 		 		 	by:	 	 /s/ John Cadeddu

		 		 		 		 	John Cadeddu, Managing Director
			
		 		 	DAG VENTURES, L.P.
				
		 		 	By:	 	 DAG Ventures Management, LLC,
 its
General Partner

					
		 		 		 	by:	 	 /s/ John Cadeddu

		 		 		 		 	John Cadeddu, Managing Director
			
		 		 	DAG VENTURES GP FUND, LLC
				
		 		 	By:	 	 DAG Ventures Management, LLC,
 its
Managing Member

					
		 		 		 	by:	 	 /s/ John Cadeddu

		 		 		 		 	John Cadeddu, Managing Director
			
		 		 	BLACKBOARD VENTURES INC.
					
		 		 		 	by:	 	 /s/ Terry Woodard

		 		 		 		 	Terry Woodard, Portfolio Manager
			
		 		 	DAG VENTURES I-N, LLC
				
		 		 	By:	 	 DAG Ventures Management, LLC,
 its
Managing Member

					
		 		 		 	by:	 	 /s/ John Cadeddu

		 		 		 		 	John Cadeddu, Managing Director

 [Signature Page to XDx, Inc. Sixth Amended and Restated Investors’ Rights Agreement] 

							
	THE INVESTORS:	 		 	KPCB HOLDINGS, INC., AS NOMINEE
				
		 		 	By:	 	 /s/ Eric Keller

		 		 	Name:	 	Eric Keller
		 		 	Title:	 	President
				
		 		 	Address:	 	c/o Kleiner Perkins Caufield Byers
		 		 		 	2750 Sand Hill Road
		 		 		 	Menlo Park, CA 94025
		 		 		 	Facsimile: 650.233.0378
		 		 		 	Attention: Risa Stack
			
	THE INVESTORS:	 		 	TPG VENTURES, L.P.
				
		 		 	By:	 	TPG Ventures GenPar, L.P.
		 		 	By:	 	TPG Venture Advisors, LLC
				
		 		 	By:	 	 /s/ Jeffery D. Ekberg

		 		 	Name:	 	Jeffery D. Ekberg
		 		 	Title:	 	Vice President
				
		 		 	Address:	 	301 Commerce St., Ste. 3300
		 		 		 	Fort Worth, Texas 76102
		 		 		 	Attn: Jeffery D. Ekberg
			
		 		 	TPG BIOTECHNOLOGY PARTNERS, L.P.
				
		 		 	By:	 	TPG Biotechnology GenPar, L.P.
		 		 	By:	 	TPG Biotech Advisors, LLC
				
		 		 	By:	 	 /s/ Jeffery D. Ekberg

		 		 	Name:	 	Jeffery D. Ekberg
		 		 	Title:	 	Vice President
				
		 		 	Address:	 	301 Commerce St., Ste. 3300
		 		 		 	Fort Worth, Texas 76102
		 		 		 	Attn: Jeffery D. Ekberg

 [Signature Page to XDx, Inc. Sixth Amended and Restated Investors’ Rights Agreement] 

							
	THE INVESTORS:	 		 	SPROUT CAPITAL IX, L.P.
				
		 		 	By:	 	DLJ Capital Corporation
		 		 	Its:	 	Managing General Partner
			
		 		 	 /s/ Vijay K. Lathi

		 		 	By:	 	Vijay K. Lathi
		 		 	Its:	 	Attorney in Fact
			
		 		 	SPROUT ENTREPRENEURS FUND, L.P.
				
		 		 	By:	 	DLJ Capital Corporation
		 		 	Its:	 	General Partner
			
		 		 	 /s/ Vijay K. Lathi

		 		 	By:	 	Vijay K. Lathi
		 		 	Its:	 	Attorney in Fact
			
	THE INVESTORS:	 		 	INTEGRAL CAPITAL PARTNERS VI, L.P.
			
		 		 	 By Integral Capital Management VI, LLC

its General Partner

				
		 		 	By:	 	 /s/ Pamela K. Hagenah

		 		 	Name:	 	Pamela K. Hagenah
		 		 	Title:	 	Manager

 [Signature Page to XDx, Inc. Sixth Amended and Restated Investors’ Rights Agreement] 

							
	THE INVESTORS:	 		 	BAY AREA EQUITY FUND I, L.P.
			
		 		 	 By: Bay Area Equity Fund Managers I, L.L.C.,

its General Partner

				
		 		 	By:	 	 /s/ Nancy E. Pfund

		 		 	Name: Nancy E. Pfund
		 		 	Title: Managing Member
			
	THE INVESTORS:	 		 	Burrill Life Sciences Capital Fund, L.P.
		 		 	By:	 	 Burrill & Company (Life Sciences GP), LLC

Its General Manager

				
		 		 	By:	 	 /s/ Steven Burrill

		 		 	Name: G. Steven Burrill
		 		 	Title: Managing Manager
			
		 		 	Address: One Embarcadero Center, Suite 2700
		 		 		 	San Francisco, CA 94111
				
		 		 	Fax:	 	(415) 591-5401
			
		 		 	Burrill Indiana Life Sciences Capital Fund, L.P.
		 		 	By:	 	 Burrill & Company (Indiana GP), LLC
 Its
General Manager

				
		 		 	By:	 	 /s/ Steven Burrill

		 		 	Name: G. Steven Burrill
		 		 	Title: Managing Member
			
		 		 	Address: One Embarcadero Center, Suite 2700
		 		 		 	San Francisco, CA 94111
				
		 		 	Fax:	 	(415) 591-5401

 [Signature Page to XDx, Inc. Sixth Amended and Restated Investors’ Rights Agreement] 

							
	THE INVESTORS:	 		 	Leader Equity LLC
		 		 	By its Manager: Leader Ventures, LLC
				
		 		 	By:	 	 /s/ Robert Molke

		 		 	Name: Robert W. Molke
		 		 	Title: Managing Director
			
		 		 	Address:
				
		 		 	Fax:	 	
			
	THE INVESTORS:	 		 	PWP PARTNERSHIP FUND, LLC
		 		 	By:	 	
				
		 		 	By:	 	 /s/ Nathaniel T. Cornell

		 		 	Name: Nathaniel T. Cornell
		 		 	Title: Managing Director
			
		 		 	Address:
				
		 		 	Fax:	 	
			
	THE INVESTORS:	 		 	BRISTOL-MYERS SQUIBB COMPANY
				
		 		 	By:	 	 /s/ Jeremy Levin

		 		 	Jeremy M. Levin, Senior Vice President
		 		 	Bristol-Myers Squibb Company
			
		 		 	Address: Route 206 & Provinceline Road
		 		 		 	P.O. Box 4000
		 		 		 	Princeton, NJ 08543-4000
		 		 	Telephone: 609-252-5333
		 		 	Fax: 609-252-7212
		 		 	Email: jeremy.levin@bms.com

 [Signature Page to XDx, Inc. Sixth Amended and Restated Investors’ Rights Agreement] 

							
	THE INVESTORS:	 		 	 LABORATORY CORPORATION OF AMERICA HOLDINGS,

a Delaware corporation

				
		 		 	By:	 	 /s/ A. Scott Walton

		 		 	Name: Scott Walton
		 		 	Title: Exec. VP of Esoteric Business
			
		 		 	Laboratory Corporation of America Holdings
		 		 	358 South Main Street,
		 		 	Burlington, North Carolina 27215
		 		 	Attention:
			
	THE INVESTORS:	 		 	AMT CONSULTING
				
		 		 	By:	 	 /s/ Jonathan Freudman

		 		 	Name: Jonathan Freudman
		 		 	Title: President
			
	THE INVESTORS:	 		 	 /s/ John Altman

		 		 	JOHN AND LESLIE ALTMAN
			
	THE INVESTORS:	 		 	CN INVESTMENT PARTNERS, L.P.
				
		 		 	By:	 	 /s/ Ali Nezhat

		 		 	Name: Ali Nezhat
		 		 	Title: General Partner

 [Signature Page to XDx, Inc. Sixth Amended and Restated Investors’ Rights Agreement 2012 Closing]

							
	THE INVESTORS:	 		 	COMERCIAL SAN ANTONIO S.A.
				
		 		 	By:	 	 /s/ Francisco J. Verstraeten

		 		 	Name: Francisco J. Verstraeten
		 		 	Title: Attorney in Fact
			
	THE INVESTORS:	 		 	BRUCE H. PHELPS
			
		 		 	 /s/ Bruce H. Phelps

			
	THE INVESTORS:	 		 	MARK LOVICH
			
		 		 	 /s/ Mark Lovich

			
	THE INVESTORS:	 		 	GEORGE MATCUK
			
		 		 	 /s/ George Matcuk

			
	THE INVESTORS:	 		 	JOSEPH MAOUAD REVOCABLE TRUST
				
		 		 	By:	 	 /s/ Joseph Maouad

		 		 	Name: Joseph Maouad
		 		 	Title:                                   
                                         
                     
	THE INVESTORS:	 		 		 	
			
		 		 	MICHAEL J. DANAHER
			
		 		 	 /s/ Michael Danaher

 [Signature Page to XDx, Inc. Sixth Amended and Restated Investors’ Rights Agreement 2012 Closing]

							
	THE INVESTORS:	 		 	MIDDLEFIELD VENTURES
				
		 		 	By:	 	 /s/ Robert Paul Pacileo Jr.

		 		 	Name: Robert Paul Pacileo Jr.
		 		 	Title: Assistant Secretary
			
	THE INVESTORS:	 		 	TRIPLEPOINT CAPITAL LLC
				
		 		 	By:	 	 /s/ Sajal Srivastava

		 		 	Name: Sajal Srivastava
		 		 	Title: Chief Operating Officer
			
	THE INVESTORS:	 		 	STERTZER FAMILY TRUST
				
		 		 	By:	 	 /s/ Simon H. Stertzer

		 		 	Name: Simon H. Stertzer
		 		 	Title: Trustee
			
	THE INVESTORS:	 		 	OCIUS MEDICAL INFORMATICS, LLC
				
		 		 	By:	 	 /s/ Todd Frech

		 		 	Name: Todd Frech
		 		 	Title: Sr. Partner

 [Signature Page to XDx, Inc. Sixth Amended and Restated Investors’ Rights Agreement 2012 Closing]

 EXHIBIT A 

Investors 
 List of
Preferred Stockholders 
 LIST OF SERIES A HOLDERS: 

Bluestone Holdings Limited* 
 CN Investment Partners, L.P.* 

Commercial San Antonio S.A* 
 James M. Shapiro, Trustee of the
James and Sarah Shapiro Family Trust dated 9/91 
 John Urquhart CGM (Citigroup Global Markets) IRA Custodian* 

K. David Crockett* 
 Michael J. Danaher* 

Modern Version Limited* 
 OCI Ltd.* 

Paul G. Yock and Cynthia A. Yock, Trustee of the Yock Revocable Trust dated 7/21/93 

Randall J. Lee* 
 Stephen Dorros, Trustee of the Gerald Dorros and
Myra Dorros Irrevocable trust 
 Stertzer Family Trust* 
 Vichon
Nevelle, S.A.* 
 Wally S. Buch, Trustee of the Buch 1993 Revocable Trust* 

WS Investment 2000A 
 LIST OF SERIES B HOLDERS: 

Bluestone Holdings Limited* 
 CN Investment Partners L.P.* 

Commercial San Antonio S.A.* 
 Domini Kelly 

Episode Holdings, Inc.* 
 Jeffrey J. Kimbell 

Joseph Maouad, Trustee FBO Joseph Maouad Revocable Trust U/A/D 01/03/03* 

Michael J. Danaher 
 OCI Ltd.* 

Sanjeev S. Judge* 
 Stephen Dorros, Trustee of the Gerald Dorros
and Myra Dorros Irrevocable Trust 
 Stertzer Family Trust* 

Stertzer Gamma Trust* 
 Torcept (formerly known as Dual Dimensions
Limited)* 
 Vichon Nevelle S.A.* 
 Windrock Enterprises, LLC

 WS Investment Company 
 WS Investment Company 2000B 

 LIST OF SERIES C HOLDERS: 

Avi Kulkarni* 
 Bluestone Holdings Limited* 

Comercial San Antonio S.A.* 
 Duke University Special Ventures
Fund, Inc. 
 Episode Holdings, Inc.* 
 Judith Wilbur* 

Judy Kishner 
 Julie and Adam Cohen* 

KPCB Holdings, Inc., as nominee 
 Macdonald (Don) Morris 

Michael J. Danaher 
 Pierre Cassigneul* 

Sanjeev S. Judge* 
 Stertzer Family Trust* 

The Elizabeth and Steven Rosenberg Trust dtd 9/28/00* 
 TPG
Biotechnology Partners, L.P. 
 TPG Ventures, L.P. 
 Vichon
Nevelle, S.A.* 
 WS Investment Company, LLC 
 LIST OF
SERIES D HOLDERS: 
 Bay Area Equity Fund, L.P. 
 Burrill
Indiana Life Sciences Capital Fund, L.P. 
 Burrill Life Sciences Capital Fund, L.P. 

Integral Capital Partners VI, L.P. 
 KPCB Holdings, Inc., as
nominee 
 Sprout Capital IX, L.P. 
 Sprout Entrepreneurs Fund,
L.P. 
 The Board of Trustees of the Leland Stanford Junior University (DAPER I) 

TPG Biotechnology Partners, L.P. 
 TPG Ventures, L.P. 

 LIST OF SERIES E HOLDERS: 

Bay Area Equity Fund I, L.P. 
 Blackboard Ventures Inc. 

Burrill Indiana Life Sciences Capital Fund, L.P. 
 Burrill Life
Sciences Capital Fund, L.P. 
 DAG Ventures GP Fund, LLC 
 DAG
Ventures I-N, LLC 
 DAG Ventures QP, L.P. 
 DAG Ventures, L.P.

 Integral Capital Partners VI, L.P. 
 Intel Capital (Cayman)
Corporation 
 KPCB Holdings, Inc., as nominee 
 Sprout Capital
IX, L.P. 
 Sprout Entrepreneurs Fund, L.P. 
 TPG Biotechnology
Partners, L.P. 
 TPG Ventures, L.P. 
 LIST OF SERIES F
INVESTORS: 
 Bay Area Equity Fund I, L.P. 
 Blackboard
Ventures Inc. 
 Burrill Indiana Life Sciences Capital Fund, L.P. 

Burrill Life Sciences Capital Fund, L.P. 
 DAG Ventures GP Fund,
LLC 
 DAG Ventures I-N, LLC 
 DAG Ventures QP, L.P. 

DAG Ventures, L.P. 
 Integral Capital Partners VI, L.P. 

Intel Capital Corporation 
 James McKay Armstrong 

KPCB Holdings, Inc., as nominee 
 Leader Equity, LLC 

PWP Partnership Fund, LLC 
 Sprout Capital IX, L.P. 

Sprout Entrepreneurs Fund, L.P. 
 TPG Biotechnology Partners, L.P.

 TPG Ventures, L.P. 
 TriplePoint Capital LLC 

WS Investment Company (2007A) 
 WS Investment Company (2007C) 

 LIST OF SERIES G INVESTORS: 

Bristol-Myers Squibb Company* 
 Blackboard Ventures Inc. 

Burrill Indiana Life Sciences Capital Fund, L.P. 
 Burrill Life
Sciences Capital Fund, L.P. 
 DAG Ventures GP Fund, LLC 
 DAG
Ventures I-N, LLC 
 DAG Ventures QP, L.P. 
 DAG Ventures, L.P.

 Integral Capital Partners VI, L.P. 
 Intel Capital
Corporation 
 KPCB Holdings, Inc., as nominee 
 Sprout Capital
IX, L.P. 
 TPG Biotechnology Partners, L.P. 
 Leader Equity,
LLC 
 John and Leslie Altman 
 AMT Consulting 

James McKay Armstrong 
 Bay Area Equity Fund I, L.P. 

CN Investment Partners, L.P. 
 Comercial San Antonio S.A. 

Michael Danaher and Carol Lee Danaher, Trustees of the Danaher Family Trust dated June 29, 2004 

Gerald Dorros and Myra S. Dorros Revocable Trust 
 Duke University
Special Ventures Fund, Inc. 
 Domini Kelly 
 Jeffrey Kimbell

 Judy Kishner 
 Laboratory Corporation of America Holdings

 Mark Lovich 
 George Matcuk 

Joseph Maouad Revocable Trust 
 Middlefield Ventures 

Macdonald Morris 
 Ocius Medical Informatics LLC 

Bruce H. Phelps 
 PWP Partnership Fund, LLC 

James and Sarah Shapiro Family Trust 
 Sprout Entrepreneurs Fund,
L.P. 
 The Board of Trustees of the Leland Stanford Junior University (DAPER I) 

Stertzer Family Trust 
 TPG Biotech Reinvest AIV, L.P. 

TPG Ventures Reinvest AIV, L.P. 
 TriplePoint Capital LLC 

Vichon Nevelle, SA 
 Windrock Enterprises, LLC 

WS Investment Company 
 WS Investment Company, LLC 

WS Investment Company, LLC (2000A) 

 WS Investment Company, LLC (2000B) 

WS Investment Company, LLC (2001A) 
 WS Investment Company, LLC
(2007A) 
 WS Investment Company, LLC (2007C) 
 Yock Revocable
Trust Dated 7/21/93 
  

	*	Preferred Stock held by Investor was converted to Common Stock of the Company.Prepared by R.R. Donnelley Financial -- EX-10.1

 Exhibit 10.1 

CAREDX, INC. 

INDEMNIFICATION AGREEMENT 

This Indemnification Agreement (this “Agreement”) is dated as of
[            , 20    ] (the “Effective Date”), and is between CareDx, Inc., a Delaware corporation (the “Company”), and
[insert name of indemnitee] (“Indemnitee”). 
 RECITALS 

A. Indemnitee’s service to the Company substantially benefits the Company. 

B. Individuals are reluctant to serve as directors or officers of corporations or in certain other capacities unless they are provided with
adequate assurance of protection through insurance or indemnification against the risks of claims and actions against them arising out of such service. 

C. Indemnitee does not regard the protection currently provided by applicable law, the Company’s governing documents and any insurance as
adequate under the present circumstances, and Indemnitee may not be willing to serve as a director or officer without additional protection. 

D. In order to induce Indemnitee to continue to provide services to the Company, it is reasonable, prudent and necessary for the Company to
contractually obligate itself to indemnify, and to advance expenses on behalf of, Indemnitee as permitted by applicable law. 
 E. This
Agreement is a supplement to and in furtherance of the indemnification provided in the Company’s certificate of incorporation, bylaws and applicable law, and any resolutions adopted pursuant thereto, and this Agreement shall not be deemed a
substitute therefor, nor shall this Agreement be deemed to limit, diminish or abrogate any rights of Indemnitee thereunder. 
 The parties
therefore agree as follows: 
 1. Definitions.  

(a) A “Change in Control” shall be deemed to occur upon the earliest to occur after the date of this Agreement of any
of the following events: 
 (i) Acquisition of Stock by Third Party. Any Person (as defined below) is or becomes the Beneficial Owner
(as defined below), directly or indirectly, of securities of the Company representing fifty percent (50%) or more of the combined voting power of the Company’s then outstanding securities; 

(ii) Change in Board Composition. During any period of two (2) consecutive years (not including any period prior to the Effective
Date), individuals who at the beginning of such period constitute the Company’s board of directors, and any new directors (other than a director designated by a person who has entered into an agreement with the Company to effect a transaction
described in Sections 1(a)(i), 1(a)(iii) or 1(a)(iv)) whose election by the board of directors or nomination for election by the Company’s stockholders was approved by a vote of at least a majority of the directors then-still in office,
who either were directors at the beginning of the period or whose election or nomination for election was previously so approved, cease for any reason to constitute at least a majority of the members of the Company’s board of directors; 

 (iii) Corporate Transactions. A merger or consolidation of the Company with any other
entity, other than a merger or consolidation which would result in the voting securities of the Company outstanding immediately prior to such merger or consolidation continuing to represent (either by remaining outstanding or by being converted into
voting securities of the surviving entity) at least half of the combined voting power of the voting securities of the surviving entity outstanding immediately after such merger or consolidation; 

(iv) Liquidation. The approval by the stockholders of the Company of a complete liquidation of the Company or an agreement for the sale
or disposition by the Company of all or substantially all of the Company’s assets; and 
 (v) Other Events. Any other event of a
nature that would be required to be reported in response to Item 6(e) of Schedule 14A of Regulation 14A (or in response to any similar item on any similar schedule or form) promulgated under the Securities Exchange Act of 1934, as amended,
whether or not the Company is then subject to such reporting requirement. 
 For purposes of this Section 1(a), the following terms
shall have the following meanings: 
 (1) “Person” shall have the meaning as set forth in Sections 13(d) and
14(d) of the Securities Exchange Act of 1934, as amended; provided, however, that “Person” shall exclude (i) the Company, (ii) any trustee or other fiduciary holding securities under an employee benefit plan
of the Company, and (iii) any corporation owned, directly or indirectly, by the stockholders of the Company in substantially the same proportions as their ownership of stock of the Company. 

(2) “Beneficial Owner” shall have the meaning given to such term in Rule 13d-3 under the Securities Exchange Act
of 1934, as amended; provided, however, that “Beneficial Owner” shall exclude any Person otherwise becoming a Beneficial Owner by reason of (i) the stockholders of the Company approving a merger of the Company
with another entity or (ii) the Company’s board of directors approving a sale of securities by the Company to such Person. 
 (b)
“Corporate Status” describes the status of a person who is or was a director, trustee, general partner, managing member, officer, employee, agent or fiduciary of the Company or any other Enterprise. 

(c) “DGCL” means the General Corporation Law of the State of Delaware. 

(d) “Disinterested Director” means a director of the Company who is not and was not a party to the Proceeding in
respect of which indemnification is sought by Indemnitee. 
 (e) “Enterprise” means the Company and any other
corporation, partnership, limited liability company, joint venture, trust, employee benefit plan or other enterprise of which Indemnitee is or was serving at the request of the Company as a director, trustee, general partner, managing member,
officer, employee, agent or fiduciary. 
 (f) “Expenses” include all attorneys’ fees, retainers, court costs,
transcript costs, fees and costs of experts, witness fees, travel expenses, duplicating costs, printing and binding costs, telephone charges, postage, delivery service fees, and all other disbursements or expenses actually and reasonably, and of the

  
 2 

 
types customarily, incurred by Indemnitee, or on his or her behalf, in connection with prosecuting, defending, preparing to prosecute or defend, investigating, being or preparing to be a witness
in, or otherwise participating in, a Proceeding. Expenses also include (i) Expenses incurred in connection with any appeal resulting from any Proceeding, including without limitation the premium, security for, and other costs relating to any
cost bond, supersedeas bond or other appeal bond or their equivalent, and (ii) for purposes of Section 12(d), Expenses incurred by Indemnitee in connection with the interpretation, enforcement or defense of Indemnitee’s rights under
this Agreement or under any directors’ and officers’ liability insurance policies maintained by the Company . Expenses, however, shall not include amounts paid in settlement by Indemnitee or the amount of judgments or fines against
Indemnitee. 
 (g) “Independent Counsel” means a law firm, or a partner or member of a law firm, that is experienced
in matters of corporation law and neither currently is, as of the time the request for indemnification is made nor in the previous five (5) years has been, retained to represent (i) the Company or Indemnitee in any matter material to
either such party (other than as Independent Counsel with respect to matters concerning Indemnitee under this Agreement, or other indemnitees under similar indemnification agreements), or (ii) any other party to the Proceeding giving rise to a
claim for indemnification hereunder. Notwithstanding the foregoing, the term “Independent Counsel” shall not include any person who, under the applicable standards of professional conduct then-prevailing, would have a
conflict of interest in representing either the Company or Indemnitee in an action to determine Indemnitee’s rights under this Agreement. 

(h) “Proceeding” means any threatened, pending or completed action, suit, arbitration, mediation, alternate dispute
resolution mechanism, investigation, inquiry, administrative hearing or proceeding, or claim, issue or matter therein, whether brought in the right of the Company, a Subsidiary or otherwise, and whether of a civil, criminal, administrative or
investigative nature, including any appeal therefrom, and including without limitation any such Proceeding pending as of the Effective Date, in which Indemnitee was, is or will be involved as a party, a potential party, a non-party witness or
otherwise by reason of (i) the fact that Indemnitee is or was a director or officer of the Company or of a Subsidiary, or (ii) the fact or assertion that he or she is or was serving at the request of the Company or of a Subsidiary as a
director, trustee, general partner, managing member, officer, employee, agent or fiduciary of the Company, a Subsidiary or any other Enterprise, in each case whether or not serving in such capacity at the time any liability or Expense is incurred
for which indemnification or advancement of expenses can be provided under this Agreement. 
 (i) “Subsidiary” means
any entity of which more than 50% of the outstanding voting securities is owned directly or indirectly by the Company. 
 (j) Reference to
“other enterprises” shall include employee benefit plans; references to “fines” shall include any excise taxes assessed on a person with respect to any employee benefit plan; references to
“serving at the request of the Company” shall include any service as a director, officer, employee or agent of the Company or of a Subsidiary which imposes duties on, or involves services by, such director, officer, employee
or agent with respect to an employee benefit plan, its participants or beneficiaries; and a person who acted in good faith and in a manner he or she reasonably believed to be in the best interests of the participants and beneficiaries of an employee
benefit plan shall be deemed to have acted in a manner “not opposed to the best interests of the Company” as referred to in this Agreement. 

2. Indemnity in Third-Party Proceedings. The Company shall indemnify Indemnitee in accordance with the provisions of this
Section 2 if Indemnitee is, or is threatened to be made, a party to or a participant in any Proceeding, other than a Proceeding by or in the right of the Company to procure a judgment in its favor. Pursuant to this Section 2, Indemnitee
shall be indemnified to the fullest extent permitted by applicable law against all Expenses, judgments, fines and amounts paid in settlement (if, and only if, such 

  
 3 

 
settlement is approved in advance by the Company, which approval shall not be unreasonably withheld) in connection with such Proceeding , if Indemnitee acted in good faith and in a manner he or
she reasonably believed to be in or not opposed to the best interests of the Company and, with respect to any criminal action or proceeding, had no reasonable cause to believe that his or her conduct was unlawful. 

3. Indemnity in Proceedings by or in the Right of the Company. The Company shall indemnify Indemnitee in accordance with the provisions
of this Section 3 if Indemnitee is, or is threatened to be made, a party to or a participant in any Proceeding by or in the right of the Company to procure a judgment in its favor. Pursuant to this Section 3, Indemnitee shall be
indemnified to the fullest extent permitted by applicable law against all Expenses in connection with such Proceeding , if Indemnitee acted in good faith and in a manner he or she reasonably believed to be in or not opposed to the best interests of
the Company. No indemnification for Expenses shall be made under this Section 3 in respect of any claim, issue or matter as to which Indemnitee shall have been adjudged by a court of competent jurisdiction to be liable to the Company, unless
and only to the extent that the Delaware Court of Chancery shall determine upon application that, despite the adjudication of liability but in view of all the circumstances of the case, Indemnitee is fairly and reasonably entitled to indemnification
for such expenses as the Delaware Court of Chancery shall deem proper. 
 4. Indemnification for Expenses of a Party Who is Wholly or
Partly Successful. To the extent that Indemnitee is a party to or a participant in and is successful (on the merits or otherwise) in defense of any Proceeding or any claim, issue or matter therein, the Company shall indemnify Indemnitee against
all Expenses in connection therewith. To the extent permitted by applicable law, if Indemnitee is not wholly successful in such Proceeding but is successful, on the merits or otherwise, in defense of one or more but fewer than all claims, issues or
matters in such Proceeding, the Company shall indemnify Indemnitee against all Expenses in connection with (a) each successfully resolved claim, issue or matter and (b) any claim, issue or matter related to any such successfully resolved
claim, issuer or matter. For purposes of this Section 4, the termination of any claim, issue or matter in such a Proceeding by dismissal, with or without prejudice, shall be deemed to be a successful result as to such claim, issue or matter.

 5. Indemnification for Expenses of a Witness. To the extent that Indemnitee is, by reason of his or her Corporate Status, a
witness in any Proceeding to which Indemnitee is not a party, Indemnitee shall be indemnified to the extent permitted by applicable law against all Expenses in connection therewith. 

6. Additional Indemnification. 

(a) Notwithstanding any limitation in Sections 2, 3 or 4, above, the Company shall indemnify Indemnitee to the fullest extent permitted by
applicable law if Indemnitee is, or is threatened to be made, a party to or a participant in any Proceeding (including a Proceeding by or in the right of the Company to procure a judgment in its favor) against all Expenses, judgments, fines and
amounts paid in settlement (if, and only if, such settlement is approved in advance by the Company, which approval shall not be unreasonably withheld) in connection with the Proceeding . 

(b) For purposes of Section 6(a), the meaning of the phrase “to the fullest extent permitted by applicable law”
shall include, but not be limited to: 
 (i) the fullest extent permitted by the provision of the DGCL that authorizes or contemplates
additional indemnification by agreement, or the corresponding provision of any amendment to or replacement of the DGCL; and 

  
 4 

 (ii) the fullest extent authorized or permitted by any amendments to or replacements of the DGCL
adopted after the date of this Agreement that increase the extent to which a corporation may indemnify its officers and directors. 
 7.
Exclusions. Notwithstanding any provision in this Agreement, the Company shall not be obligated under this Agreement to make any indemnity or provide any benefit to Indemnitee under this Agreement or otherwise, in connection with any
Proceeding (or any part of any Proceeding): 
 (a) for which payment has actually been made to or on behalf of Indemnitee under any statute,
insurance policy, indemnity provision, vote or otherwise, except with respect to any excess beyond the amount paid, subject to any subrogation rights set forth in Section 15; 

(b) for an accounting or disgorgement of profits pursuant to Section 16(b) of the Securities Exchange Act of 1934, as amended, or similar
provisions of federal, state or local statutory law or common law, if Indemnitee is held liable therefor (including pursuant to any settlement arrangements); 

(c) for any reimbursement of the Company by Indemnitee of any bonus or other incentive-based or equity-based compensation or of any profits
realized by Indemnitee from the sale of securities of the Company, as required in each case under the Securities Exchange Act of 1934, as amended (including any such reimbursements that arise from an accounting restatement of the Company pursuant to
Section 304 of the Sarbanes-Oxley Act of 2002 (the “Sarbanes-Oxley Act”), or the payment to the Company of profits arising from the purchase and sale by Indemnitee of securities in violation of Section 306 of the
Sarbanes-Oxley Act), if Indemnitee is held liable therefor (including pursuant to any settlement arrangements); 
 (d) initiated by
Indemnitee, including against the Company or its directors, officers, employees, agents or other indemnitees, unless (i) the Company’s board of directors authorized the Proceeding (or the relevant part of the Proceeding) prior to its
initiation, (ii) the Company provides the indemnification, in its sole discretion, pursuant to the powers vested in the Company under applicable law, (iii) otherwise authorized in Section 12(d) or (iv) otherwise required by
applicable law or the Company’s bylaws; or 
 (e) if prohibited by applicable law. 

8. Advances of Expenses. To the extent indemnity is provided pursuant to Sections 2, 3 or 4, above, or otherwise in this Agreement, the
Company shall advance the Expenses incurred by Indemnitee in connection with any such Proceeding, and such advancement shall be made as soon as reasonably practicable, but in any event no later than 30 days, after the receipt by the Company of a
written statement or statements requesting such advances from time to time (which shall include invoices received by Indemnitee in connection with such Expenses but, in the case of invoices in connection with legal services, any references to legal
work performed or to expenditure made that would cause Indemnitee to waive any privilege accorded by applicable law shall not be included with the invoice). Reimbursements hereunder shall be deemed advances, and shall be unsecured and interest free
and made without regard to Indemnitee’s ability to repay such advances. Indemnitee hereby undertakes to repay any such advance to the extent that it is ultimately determined that Indemnitee is not entitled to be indemnified by the Company. This
Section 8 shall not apply to prevent reimbursement to the extent advancement is prohibited by law, or with respect to Proceeding for which indemnity is not permitted under this Agreement, but shall apply to any Proceeding referenced in
Section 7(b) or 7(c) prior to a determination that Indemnitee is not entitled to be indemnified by the Company. 

  
 5 

 9. Procedures for Notification and Defense of Claim. 

(a) Indemnitee shall notify the Company in writing of any matter with respect to which Indemnitee intends to seek indemnification or
advancement of Expenses as soon as reasonably practicable following the receipt by Indemnitee of notice thereof. The written notification to the Company shall include, in reasonable detail, a description of the nature of the Proceeding and the facts
underlying the Proceeding. The failure by Indemnitee to notify the Company will not relieve the Company from any liability which it may have to Indemnitee hereunder or otherwise than under this Agreement, and any delay in so notifying the Company
shall not constitute a waiver by Indemnitee of any rights, except to the extent that such failure or delay materially prejudices the Company. 

(b) If, at the time of the receipt of a written notice of a Proceeding pursuant to the terms hereof, the Company has directors’ and
officers’ liability insurance in effect, the Company shall give prompt notice of the commencement of the Proceeding to such insurers in accordance with the procedures set forth in the applicable policies. The Company shall thereafter take all
commercially-reasonable actions to cause such insurers to pay, on behalf of Indemnitee, all amounts payable as a result of such Proceeding in accordance with the terms of such policies. 

(c) In the event the Company may be obligated to make any indemnity in connection with a Proceeding, the Company shall be entitled to assume
the defense of such Proceeding with counsel approved by Indemnitee, which approval shall not be unreasonably withheld, upon the delivery to Indemnitee of written notice of the Company’s election to do so. After delivery of such notice, approval
of such counsel by Indemnitee and the retention of such counsel by the Company, the Company will not be liable to Indemnitee for any fees or expenses of counsel subsequently incurred by Indemnitee with respect to the same Proceeding. Notwithstanding
the Company’s assumption of the defense of any such Proceeding, the Company shall be obligated to pay the fees and expenses of Indemnitee’s counsel to the extent (i) the employment of counsel by Indemnitee is authorized by the
Company, (ii) counsel for the Company or Indemnitee shall have reasonably concluded that there is a conflict of interest between the Company and Indemnitee in the conduct of any such defense, such that Indemnitee needs to be separately
represented, (iii) the fees and expenses are non-duplicative and reasonably incurred in connection with Indemnitee’s role in the Proceeding despite the Company’s assumption of the defense, (iv) the Company is not financially or
legally able to perform its defense obligations, or (v) the Company shall not have retained, or shall not continue to retain, such counsel to defend such Proceeding; provided that Indemnitee’s counsel conducts the defense of such
Proceeding actively and diligently. The Company shall have the right to conduct such defense as it sees fit in its sole discretion. Regardless of any provision in this Agreement, Indemnitee shall have the right to employ counsel in any Proceeding at
Indemnitee’s personal expense. The Company shall not be entitled, without the consent of Indemnitee, to assume the defense of any claim brought by or in the right of the Company. 

(d) Indemnitee shall give the Company such information and cooperation in connection with the Proceeding as may be reasonably appropriate. 

(e) The Company shall not be liable to indemnify Indemnitee for any settlement of any Proceeding (or any part thereof) without the
Company’s prior written consent, which shall not be unreasonably withheld. 
 (f) The Company shall have the right to settle any
Proceeding (or any part thereof) without the consent of Indemnitee. 

  
 6 

 10. Procedures upon Application for Indemnification.  

(a) To obtain indemnification, Indemnitee shall submit to the Company a written request, including therein or therewith such documentation and
information as is reasonably available to Indemnitee and as is reasonably necessary or as the Company may reasonably request to determine whether and to what extent Indemnitee is entitled to indemnification following the final disposition of the
Proceeding. The Company shall, as soon as reasonably practicable after receipt of such a request for indemnification, advise the board of directors that Indemnitee has requested indemnification. Any delay in providing the request will not relieve
the Company from its obligations under this Agreement, except to the extent such failure is prejudicial. 
 (b) Upon written request by
Indemnitee for indemnification pursuant to Section 10(a), a determination, if required by applicable law, with respect to Indemnitee’s entitlement thereto shall be made in the specific case (i) if a Change in Control shall have
occurred, by Independent Counsel in a written opinion to the Company’s board of directors, a copy of which shall be delivered to Indemnitee or (ii) if a Change in Control shall not have occurred, (A) by a majority vote of the
Disinterested Directors, even though less than a quorum of the Company’s board of directors, (B) by a committee of Disinterested Directors designated by a majority vote of the Disinterested Directors, even though less than a quorum of the
Company’s board of directors, (C) if there are no such Disinterested Directors, or if such Disinterested Directors so direct, by Independent Counsel in a written opinion to the Company’s board of directors, a copy of which shall be
delivered to Indemnitee, or (D) if so directed by the Company’s board of directors, by the stockholders of the Company. If it is so determined that Indemnitee is entitled to indemnification, payment to Indemnitee shall be made within ten
(10) days after such determination. Indemnitee shall cooperate with the person, persons or entity making the determination with respect to Indemnitee’s entitlement to indemnification, including providing to such person, persons or entity
upon reasonable advance request any documentation or information that is not privileged or otherwise protected from disclosure and that is reasonably available to Indemnitee and reasonably necessary to such determination. Any Expenses incurred by
Indemnitee in so cooperating with the person, persons or entity making such determination shall be borne by the Company, to the extent permitted by applicable law. 

(c) In the event the determination of entitlement to indemnification is to be made by Independent Counsel pursuant to Section 10(b), the
Independent Counsel shall be selected as provided in this Section 10(c). If a Change in Control shall not have occurred, the Independent Counsel shall be selected by the Company’s board of directors, and the Company shall give written
notice to Indemnitee advising him or her of the identity of the Independent Counsel so selected. If a Change in Control shall have occurred, the Independent Counsel shall be selected by Indemnitee (unless Indemnitee shall request that such selection
be made by the Company’s board of directors, in which event the preceding sentence shall apply), and Indemnitee shall give written notice to the Company advising it of the identity of the Independent Counsel so selected. In either event,
Indemnitee or the Company, as the case may be, may, within ten days after such written notice of selection shall have been given, deliver to the Company or to Indemnitee, as the case may be, a written objection to such selection; provided,
however, that such objection may be asserted only on the ground that the Independent Counsel so selected does not meet the requirements of “Independent Counsel,” as defined in Section 1 of this Agreement, and the objection
shall set forth with particularity the factual basis of such assertion. Absent a proper and timely objection, the person so selected shall act as Independent Counsel. If such written objection is so made and substantiated, the Independent Counsel so
selected may not serve as Independent Counsel unless and until such objection is withdrawn or a court has determined that such objection is without merit. If, within 20 days after the later of (i) submission by Indemnitee of a written request
for indemnification pursuant to Section 10(a) hereof and (ii) the final disposition of the Proceeding, the parties have not agreed upon an Independent Counsel, either the Company or Indemnitee may petition a court of competent jurisdiction
for resolution of any objection which shall have been made by the Company or Indemnitee to the other’s selection of Independent Counsel and for the appointment as Independent Counsel of 

  
 7 

 
a person selected by the court or by such other person as the court shall designate, and the person with respect to whom all objections are so resolved or the person so appointed shall act as
Independent Counsel under Section 10(b), above. Upon the due commencement of any judicial proceeding or arbitration pursuant to Section 12(a), below, the Independent Counsel shall be discharged and relieved of any further responsibility in
such capacity (subject to the applicable standards of professional conduct then-prevailing). 
 (d) The Company agrees to pay the reasonable
fees and expenses of any Independent Counsel and to fully indemnify such counsel against any and all Expenses, claims, liabilities and damages arising out of or relating to this Agreement or its engagement pursuant hereto. 

11. Presumptions and Effect of Certain Proceedings. 

(a) In making a determination with respect to entitlement to indemnification hereunder, the person, persons or entity making such determination
shall, to the fullest extent not prohibited by applicable law, presume that Indemnitee is entitled to indemnification if Indemnitee has submitted a request for indemnification in accordance with Section 10(a) of this Agreement, and the Company
shall, to the fullest extent not prohibited by applicable law, have the burden of proof to overcome that presumption in connection with the making by such person, persons or entity of any determination contrary to that presumption. 

(b) The termination of any Proceeding, by judgment, order, settlement or conviction, or upon a plea of nolo contendere or its
equivalent, shall not (except as otherwise expressly provided in this Agreement or as required by applicable law) of itself adversely affect the right of Indemnitee to indemnification or create a presumption that Indemnitee did not act in good faith
and in a manner which he or she reasonably believed to be in or not opposed to the best interests of the Company or, with respect to any criminal Proceeding, that Indemnitee had reasonable cause to believe that his or her conduct was unlawful. 

(c) For purposes of any determination of good faith, Indemnitee shall be deemed to have acted in good faith to the extent Indemnitee relied in
good faith on (i) the records or books of account of the Enterprise, including financial statements, (ii) information supplied to Indemnitee by the officers of the Enterprise in the course of their duties, (iii) the advice of legal
counsel for the Enterprise or its board of directors, or counsel selected by any committee of the board of directors, or (iv) information or records given or reports made to the Enterprise by an independent certified public accountant, an
appraiser, investment banker or other expert selected with reasonable care by the Enterprise or its board of directors or any committee of the board of directors (including consultants or advisors formally engaged by the board or committee). The
provisions of this Section 11(c) shall not be deemed to be exclusive or to limit in any way the other circumstances in which Indemnitee may be deemed to have met the applicable standard of conduct set forth in this Agreement. 

(d) Neither the knowledge, actions nor failure to act of any other director, officer, agent or employee of the Enterprise shall be imputed to
Indemnitee for purposes of determining the right to indemnification under this Agreement. 
 12. Remedies of Indemnitee. 

(a) Subject to Section 12(e), in the event that (i) a determination is made pursuant to Section 10, above, that Indemnitee is
not entitled to indemnification under this Agreement, (ii) advancement of Expenses is not timely made pursuant to Section 8, above, or 12(d), below, (iii) no determination of entitlement to indemnification shall have been made
pursuant to Section 10, above, within 90 days after the later of the receipt by the Company of the request for indemnification or the final disposition of the Proceeding, (iv) payment of indemnification pursuant to this Agreement is not
made (A) within ten (10) days 

  
 8 

 
after a determination has been made that Indemnitee is entitled to indemnification or (B) with respect to indemnification pursuant to Sections 4 or 5, above, and 12(d), below, within 30
days after receipt by the Company of a written request therefor, or (v) the Company or any other person or entity takes or threatens to take any action to declare this Agreement void or unenforceable, or institutes any litigation or other
action or proceeding to deny, or to recover from, Indemnitee the benefits provided or intended to be provided to Indemnitee hereunder, Indemnitee shall be entitled to an adjudication in a court of competent jurisdiction of his or her entitlement to
such indemnification or advancement of Expenses. Alternatively, Indemnitee, at his or her option, may seek an award in arbitration with respect to his or her entitlement to such indemnification or advancement of Expenses, to be conducted by a single
arbitrator pursuant to the Commercial Arbitration Rules of the American Arbitration Association. Indemnitee shall commence such proceeding seeking an adjudication or an award in arbitration within 180 days following the date on which Indemnitee
first has the right to commence such proceeding pursuant to this Section 12(a); provided, however, that the foregoing clause shall not apply in respect of a proceeding brought by Indemnitee to enforce his or her rights under
Section 4, above. The Company shall not oppose Indemnitee’s right to seek any such adjudication or award in arbitration in accordance with this Agreement. 

(b) Neither (i) the failure of the Company, its board of directors, any committee or subgroup of the board of directors, Independent
Counsel or stockholders to have made a determination that indemnification of Indemnitee is proper in the circumstances because Indemnitee has met the applicable standard of conduct, nor (ii) an actual determination by the Company, its board of
directors, any committee or subgroup of the board of directors, Independent Counsel or stockholders that Indemnitee has not met the applicable standard of conduct, may be asserted or offered into evidence as a defense to the action or to create a
presumption that Indemnitee has or has not met the applicable standard of conduct. In the event that a determination shall have been made pursuant to Section 10 of this Agreement that Indemnitee is not entitled to indemnification, any judicial
proceeding or arbitration commenced pursuant to this Section 12 shall be conducted in all respects as a de novo trial, or arbitration, on the merits, and Indemnitee shall not be prejudiced by reason of that adverse determination. In any
judicial proceeding or arbitration commenced pursuant to this Section 12, the Company shall, to the fullest extent not prohibited by applicable law, have the burden of proving Indemnitee is not entitled to indemnification or advancement of
Expenses, as the case may be. 
 (c) To the fullest extent not prohibited by applicable law, the Company shall be precluded from asserting in
any judicial proceeding or arbitration commenced pursuant to this Section 12 that the procedures and presumptions of this Agreement are not valid, binding and enforceable and shall stipulate in any such court or before any such arbitrator that
the Company is bound by all the provisions of this Agreement. If a determination shall have been made pursuant to Section 10, above, that Indemnitee is entitled to indemnification, the Company shall be bound by such determination in any
judicial proceeding or arbitration commenced pursuant to this Section 12, absent (i) a misstatement by Indemnitee of a material fact, or an omission of a material fact necessary to make Indemnitee’s statements not materially
misleading, in connection with the request for indemnification, or (ii) a prohibition of such indemnification under applicable law. 

(d) To the extent not prohibited by applicable law, the Company shall indemnify Indemnitee against all Expenses that are incurred by Indemnitee
in connection with any action for indemnification or advancement of Expenses from the Company under this Agreement or under any directors’ and officers’ liability insurance policies maintained by the Company to the extent Indemnitee is
successful in such action, and, if requested by Indemnitee, the Company shall (as soon as reasonably practicable, but in any event no later than 60 days, after receipt by the Company of a written request therefor) advance such Expenses to
Indemnitee, subject to the provisions of Section 8, above. 

  
 9 

 (e) Notwithstanding anything in this Agreement to the contrary, no determination as to
entitlement to indemnification shall be required to be made prior to the final disposition of the Proceeding. 
 13. Contribution. To
the fullest extent permissible under applicable law, if the indemnification provided for in this Agreement is unavailable to Indemnitee, the Company, in lieu of indemnifying Indemnitee, shall contribute to the amounts incurred by Indemnitee, whether
for Expenses, judgments, fines or amounts paid or to be paid in settlement, in connection with any claim relating to an indemnifiable event under this Agreement, in such proportion as is deemed fair and reasonable in light of all of the
circumstances of such Proceeding in order to reflect (i) the relative benefits received by the Company and Indemnitee as a result of the events and transactions giving rise to such Proceeding; and (ii) the relative fault of Indemnitee and
the Company (and its other directors, officers, employees and agents) in connection with such events and transactions. 
 14.
Non-exclusivity; No Limitation on Indemnity Rights. The rights of indemnification and to receive advancement of Expenses as provided by this Agreement shall not be deemed exclusive of, or in any manner limit, any other rights to which
Indemnitee may at any time be entitled under applicable law, the Company’s certificate of incorporation or bylaws, any agreement, a vote of stockholders or a resolution of directors, or otherwise. To the extent that a change in Delaware law,
whether by statute or judicial decision, permits greater indemnification or advancement of Expenses than would be afforded currently under the Company’s certificate of incorporation and bylaws and this Agreement, it is the intent of the parties
hereto that Indemnitee shall enjoy by this Agreement the greater benefits so afforded by such change, subject to the restrictions expressly set forth herein or therein. Except as expressly set forth herein, no right or remedy herein conferred is
intended to be exclusive of any other right or remedy, and every other right and remedy shall be cumulative and in addition to every other right and remedy given hereunder or now or hereafter existing at law or in equity or otherwise. Except as
expressly set forth herein, the assertion or employment of any right or remedy hereunder, or otherwise, shall not prevent the concurrent assertion or employment of any other right or remedy. 

15. Primary Responsibility. The Company acknowledges that Indemnitee has certain rights to indemnification and advancement of expenses
provided by [insert name of fund] and certain affiliates thereof (collectively, the “Secondary Indemnitor”). The Company agrees that, as between the Company and the Secondary Indemnitor, the Company is primarily
responsible for amounts required to be indemnified or advanced under the Company’s certificate of incorporation or bylaws or this Agreement and any obligation of the Secondary Indemnitor to provide indemnification or advancement for the same
amounts is secondary to those Company obligations. To the extent not in contravention of any insurance policy or policies providing liability or other insurance for the Company or any director, trustee, general partner, managing member, officer,
employee, agent or fiduciary of the Company or any other Enterprise, the Company waives any right of contribution or subrogation against the Secondary Indemnitor with respect to the liabilities for which the Company is primarily responsible under
this Section 15. In the event of any payment by the Secondary Indemnitor of amounts otherwise required to be indemnified or advanced by the Company under the Company’s certificate of incorporation or bylaws or this Agreement, the Secondary
Indemnitor shall be subrogated to the extent of such payment to all of the rights of recovery of Indemnitee for indemnification or advancement of expenses under the Company’s certificate of incorporation or bylaws or this Agreement or, to the
extent such subrogation is unavailable and contribution is found to be the applicable remedy, shall have a right of contribution with respect to the amounts paid. The Secondary Indemnitor is an express third-party beneficiary of the terms of this
Section 15. 
 16. No Duplication of Payments. The Company shall not be liable under this Agreement to make any payment of
amounts otherwise indemnifiable hereunder (or for which advancement is provided hereunder) if and to the extent that Indemnitee has otherwise actually received payment for such amounts under any insurance policy, contract, agreement or otherwise,
subject to any subrogation rights set forth in Section 15. 

  
 10 

 17. Insurance. The Company shall, to the extent that the Board determines it to be
economically reasonable, maintain a policy of directors’ and officers’ liability insurance, on such terms and conditions as may be approved by the Board. 

18. Subrogation. In the event of any payment under this Agreement, the Company shall be subrogated to the extent of such payment to all
of the rights of recovery of Indemnitee, who shall execute all papers required and take all action necessary to secure such rights, including execution of such documents as are necessary to enable the Company to bring suit to enforce such rights.

 19. Services to the Company. Indemnitee agrees to serve as a director or officer of the Company or, at the request of the Company,
as a director, trustee, general partner, managing member, officer, employee, agent or fiduciary of another Enterprise, for so long as Indemnitee is duly elected or appointed or until Indemnitee tenders his or her resignation or is removed from such
position. Indemnitee may at any time and for any reason resign from such position (subject to any other contractual obligation or any obligation imposed by operation of law), in which event the Company shall have no obligation under this Agreement
to continue Indemnitee in such position. This Agreement shall not be deemed an employment contract between the Company (or any of its subsidiaries or any Enterprise) and Indemnitee. Indemnitee specifically acknowledges that any employment with the
Company (or any of its subsidiaries or any Enterprise) is at will, and Indemnitee may be discharged at any time for any reason, with or without cause, with or without notice, except as may be otherwise expressly provided in any executed, written
employment contract between Indemnitee and the Company (or any of its subsidiaries or any Enterprise), any existing formal severance policies adopted by the Company’s board of directors or, with respect to service as a director or officer of
the Company, the Company’s certificate of incorporation or bylaws or the DGCL. No such document shall be subject to any oral modification thereof. 

20. Duration. This Agreement shall commence as of the Effective Date and continue until and terminate upon the later of (a) ten
(10) years after the date that Indemnitee shall have ceased to serve as a director or officer of the Company or a Subsidiary, or as a director, trustee, general partner, managing member, officer, employee, agent or fiduciary of any other
Enterprise, as applicable, or (b) one (1) year after the final termination of any Proceeding, including any appeal, then-pending in respect of which Indemnitee is granted rights of indemnification or advancement of Expenses hereunder and
of any proceeding commenced by Indemnitee pursuant to Section 12, above, relating thereto. 
 21. Successors. This Agreement
shall be binding upon the Company and its successors and assigns, including any direct or indirect successor by purchase, merger, consolidation or otherwise to all or substantially all of the business or assets of the Company, and shall inure to the
benefit of Indemnitee and Indemnitee’s heirs, executors and administrators. The Company shall require and cause any successor (whether direct or indirect by purchase, merger, consolidation or otherwise) to all or substantially all of the
business or assets of the Company, by written agreement, expressly to assume and agree to perform this Agreement in the same manner and to the same extent that the Company would be required to perform if no such succession had taken place. 

22. Severability. Nothing in this Agreement is intended to require or shall be construed as requiring the Company to do or fail to do
any act in violation of applicable law. The Company’s inability, pursuant to court order or other applicable law, to perform its obligations under this Agreement shall not constitute a breach of this Agreement. If any provision or provisions of
this Agreement shall be held to be invalid, illegal or unenforceable for any reason whatsoever: (i) the validity, legality and enforceability of the 

  
 11 

 
remaining provisions of this Agreement (including without limitation, each portion of any section of this Agreement containing any such provision held to be invalid, illegal or unenforceable,
that is not itself invalid, illegal or unenforceable) shall not in any way be affected or impaired thereby and shall remain enforceable to the fullest extent permitted by law; (ii) such provision or provisions shall be deemed reformed to the
extent necessary to conform to applicable law and to give the maximum effect to the intent of the parties hereto; and (iii) to the fullest extent possible, the provisions of this Agreement (including, without limitation, each portion of any
section of this Agreement containing any such provision held to be invalid, illegal or unenforceable, that is not itself invalid, illegal or unenforceable) shall be construed so as to give effect to the intent manifested thereby. 

23. Enforcement. The Company expressly confirms and agrees that it has entered into this Agreement and assumed the obligations imposed
on it hereby in order to induce Indemnitee to serve as a director or officer of the Company, and the Company acknowledges that Indemnitee is relying upon this Agreement in serving as a director or officer of the Company. 

24. Entire Agreement. This Agreement constitutes the entire agreement between the parties hereto with respect to the subject matter
hereof and supersedes all prior agreements and understandings, oral, written and implied, between the parties hereto with respect to the subject matter hereof; provided, however, that this Agreement is a supplement to and in
furtherance of the Company’s obligations to Indemnitee, as provided by its certificate of incorporation and bylaws, and by applicable law. 

25. Modification and Waiver. No supplement, modification or amendment to this Agreement shall be binding unless and only to the extent
executed in writing by the parties hereto. No amendment, alteration or repeal of this Agreement shall adversely affect any right of Indemnitee under this Agreement in respect of any action taken or omitted by such Indemnitee in his or her Corporate
Status prior to such amendment, alteration or repeal. No waiver of any of the provisions of this Agreement shall constitute or be deemed a waiver of any other provision of this Agreement nor shall any waiver constitute a continuing waiver. 

26. Notices. All notices and other communications required or permitted hereunder shall be in writing and shall be mailed by registered
or certified mail, postage prepaid, sent by facsimile or electronic mail or otherwise delivered by hand, messenger or courier service addressed: 

(a) if to Indemnitee, to Indemnitee’s address, facsimile number or electronic mail address as shown on the signature page of this
Agreement or in the Company’s records, as may be updated in accordance with the provisions hereof; or 
 (b) if to the Company, to the
attention of the Chief Executive Officer or Chief Financial Officer of the Company at 3260 Bayshore Blvd., Brisbane, CA 94005, or at such other current address as the Company shall have furnished to Indemnitee, with a copy (which shall not
constitute notice) to Michael J. Danaher, Wilson Sonsini Goodrich & Rosati, P.C., 650 Page Mill Road, Palo Alto, California 94304. 

Each such notice or other communication shall for all purposes of this Agreement be treated as effective or having been given (i) if
delivered by hand, messenger or courier service, when delivered (or if sent via a nationally-recognized overnight courier service, freight prepaid, specifying next-business-day delivery, one business day after deposit with the courier),
(ii) if sent via mail, at the earlier of its receipt or five days after the same has been deposited in a regularly-maintained receptacle for the deposit of the United States mail, addressed and mailed as aforesaid, or (iii) if sent
via facsimile, upon confirmation of facsimile transfer or, if sent via electronic mail, upon confirmation of delivery when directed to the relevant electronic mail address, if sent during normal business hours of the recipient, or if
not sent during normal business hours of the recipient, then on the recipient’s next business day. 

  
 12 

 27. Applicable Law and Consent to Jurisdiction. This Agreement and the legal relations
among the parties shall be governed by, and construed and enforced in accordance with, the laws of the State of Delaware, without regard to its conflict of laws rules. Except with respect to any arbitration commenced by Indemnitee pursuant to
Section 12(a), above, or by the Company or Indemnitee pursuant to a written agreement between the Company and Indemnitee providing for such, the Company and Indemnitee hereby irrevocably and unconditionally (i) agree that any action or
proceeding arising out of or in connection with this Agreement shall be brought only in the Delaware Court of Chancery, and not in any other state or federal court in the United States of America or any court in any other country, (ii) consent
to submit to the exclusive jurisdiction of the Delaware Court of Chancery for purposes of any action or proceeding arising out of or in connection with this Agreement, (iii) appoint, to the extent such party is not otherwise subject to service
of process in the State of Delaware, Corporation Service Company, Wilmington, Delaware, as its agent in the State of Delaware as such party’s agent for acceptance of legal process in connection with any such action or proceeding against such
party with the same legal force and validity as if served upon such party personally within the State of Delaware, (iv) waive any objection to the laying of venue of any such action or proceeding in the Delaware Court of Chancery, and
(v) waive, and agree not to plead or to make, any claim that any such action or proceeding brought in the Delaware Court of Chancery has been brought in an improper or inconvenient forum. 

28. Counterparts. This Agreement may be executed in one or more counterparts, each of which shall for all purposes be deemed to be an
original but all of which together shall constitute one and the same Agreement. This Agreement may also be executed and delivered by facsimile signature and in counterparts, each of which shall for all purposes be deemed to be an original but all of
which together shall constitute one and the same Agreement. Only one such counterpart signed by the party against whom enforceability is sought needs to be produced to evidence the existence of this Agreement. 

29. Captions. The headings of the paragraphs of this Agreement are inserted for convenience only and shall not be deemed to constitute
part of this Agreement or to affect the construction thereof. 
 (signature page follows) 

  
 13 

 The parties are signing this Indemnification Agreement as of the date stated in the introductory
sentence. 
  

	
	CAREDX, INC.
	
	   

	(Signature)
	
	   

	(Print name)
	
	   

	(Title)

  

	
	[INSERT INDEMNITEE NAME]
	
	   

	(Signature)
	
	   

	(Print name)
	
	   

	(Street address)
	
	   

	(City, State and ZIP)

  
 [Signature Page to
Indemnification Agreement]

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00231-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00231-of-00352.parquet"}]]